<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cilostazol for intermittent claudication - Brown, T - 2021 | Cochrane Library</title> <meta content="Cilostazol for intermittent claudication - Brown, T - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003748.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cilostazol for intermittent claudication - Brown, T - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003748.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003748.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Cilostazol for intermittent claudication" name="citation_title"/> <meta content="Tamara Brown" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="tamara.brown@ed.ac.uk" name="citation_author_email"/> <meta content="Rachel B Forster" name="citation_author"/> <meta content="Norwegian Institute of Public Health" name="citation_author_institution"/> <meta content="Marcus Cleanthis" name="citation_author"/> <meta content="Frimley Park Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Dimitri P Mikhailidis" name="citation_author"/> <meta content="Royal Free Hospital Campus, University College London Medical School" name="citation_author_institution"/> <meta content="Gerard Stansby" name="citation_author"/> <meta content="Freeman Hospital" name="citation_author_institution"/> <meta content="Marlene Stewart" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD003748.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/06/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003748.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003748.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003748.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Cilostazol [*therapeutic use]; Intermittent Claudication [*drug therapy, etiology]; Myocardial Infarction [prevention &amp; control]; Pentoxifylline [therapeutic use]; Peripheral Vascular Diseases [complications, drug therapy]; Placebos [therapeutic use]; Platelet Aggregation Inhibitors [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Stroke [prevention &amp; control]; Tetrazoles [adverse effects, *therapeutic use]; Walking" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003748.pub5&amp;doi=10.1002/14651858.CD003748.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003748\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003748\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","th","ko","ms","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003748.pub5",title:"Cilostazol for intermittent claudication",firstPublishedDate:"Jun 30, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003748.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003748.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003748.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003748.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003748.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003748.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003748.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003748.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003748.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003748.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3557 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003748.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/appendices#CD003748-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/table_n/CD003748StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/table_n/CD003748StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cilostazol for intermittent claudication</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#CD003748-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Tamara Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#CD003748-cr-0005">Rachel B Forster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#CD003748-cr-0006">Marcus Cleanthis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#CD003748-cr-0007">Dimitri P Mikhailidis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#CD003748-cr-0008">Gerard Stansby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information#CD003748-cr-0009">Marlene Stewart</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information/en#CD003748-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 June 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003748.pub5">https://doi.org/10.1002/14651858.CD003748.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003748-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003748-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003748-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003748-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003748-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003748-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD003748-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003748-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003748-abs-0001" lang="en"> <section id="CD003748-sec-0001"> <h3 class="title" id="CD003748-sec-0001">Background</h3> <p>Peripheral arterial disease (PAD) affects between 4% and 12% of people aged 55 to 70 years, and 20% of people over 70 years. A common complaint is intermittent claudication (exercise‐induced lower limb pain relieved by rest). These patients have a three‐ to six‐fold increase in cardiovascular mortality.  Cilostazol is a drug licensed for the use of improving claudication distance and, if shown to reduce cardiovascular risk, could offer additional clinical benefits. This is an update of the review first published in 2007. </p> </section> <section id="CD003748-sec-0002"> <h3 class="title" id="CD003748-sec-0002">Objectives</h3> <p>To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication. </p> </section> <section id="CD003748-sec-0003"> <h3 class="title" id="CD003748-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, and AMED databases, and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registries, on 9 November 2020. </p> </section> <section id="CD003748-sec-0004"> <h3 class="title" id="CD003748-sec-0004">Selection criteria</h3> <p>We considered double‐blind, randomised controlled trials (RCTs) of cilostazol versus placebo, or versus other drugs used to improve claudication distance in patients with stable intermittent claudication. </p> </section> <section id="CD003748-sec-0005"> <h3 class="title" id="CD003748-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trials for selection and independently extracted data. Disagreements were resolved by discussion. We assessed the risk of bias with the Cochrane risk of bias tool. Certainty of the evidence was evaluated using GRADE. For dichotomous outcomes, we used odds ratios (ORs) with corresponding 95% confidence intervals (CIs) and for continuous outcomes we used mean differences (MDs) and 95% CIs. We pooled data using a fixed‐effect model, or a random‐effects model when heterogeneity was identified. Primary outcomes were initial claudication distance (ICD) and quality of life (QoL). Secondary outcomes were absolute claudication distance (ACD), revascularisation, amputation, adverse events and cardiovascular events. </p> </section> <section id="CD003748-sec-0006"> <h3 class="title" id="CD003748-sec-0006">Main results</h3> <p>We included 16 double‐blind, RCTs (3972 participants) comparing cilostazol with placebo, of which five studies also compared cilostazol with pentoxifylline. Treatment duration ranged from six to 26 weeks. All participants had intermittent claudication secondary to PAD. Cilostazol dose ranged from 100 mg to 300 mg; pentoxifylline dose ranged from 800 mg to 1200 mg. The certainty of the evidence was downgraded by one level for all studies because publication bias was strongly suspected. Other reasons for downgrading were imprecision, inconsistency and selective reporting. </p> <p><b>Cilostazol versus placebo</b> </p> <p>Participants taking cilostazol had a higher ICD compared with those taking placebo (MD 26.49 metres; 95% CI 18.93 to 34.05; 1722 participants; six studies; low‐certainty evidence). We reported QoL measures descriptively due to insufficient statistical detail within the studies to combine the results; there was a possible indication in improvement of QoL in the cilostazol treatment groups (low‐certainty evidence). Participants taking cilostazol had a higher ACD compared with those taking placebo (39.57 metres; 95% CI 21.80 to 57.33; 2360 participants; eight studies; very‐low certainty evidence). The most commonly reported adverse events were headache, diarrhoea, abnormal stools, dizziness, pain and palpitations. Participants taking cilostazol had an increased odds of experiencing headache compared to participants taking placebo (OR 2.83; 95% CI 2.26 to 3.55; 2584 participants; eight studies; moderate‐certainty evidence).Very few studies reported on other outcomes so conclusions on revascularisation, amputation, or cardiovascular events could not be made. </p> <p><b>Cilostazol versus pentoxifylline</b> </p> <p>There was no difference detected between cilostazol and pentoxifylline for improving walking distance, both in terms of ICD (MD 20.0 metres, 95% CI ‐2.57 to 42.57; 417 participants; one study; low‐certainty evidence); and ACD (MD 13.4 metres, 95% CI ‐43.50 to 70.36; 866 participants; two studies; very low‐certainty evidence). One study reported on QoL; the study authors reported no difference in QoL between the treatment groups (very low‐certainty evidence). No study reported on revascularisation, amputation or cardiovascular events. Cilostazol participants had an increased odds of experiencing headache compared with participants taking pentoxifylline at 24 weeks (OR 2.20, 95% CI 1.16 to 4.17; 982 participants; two studies; low‐certainty evidence). </p> </section> <section id="CD003748-sec-0007"> <h3 class="title" id="CD003748-sec-0007">Authors' conclusions</h3> <p>Cilostazol has been shown to improve walking distance in people with intermittent claudication. However, participants taking cilostazol had higher odds of experiencing headache. There is insufficient evidence about the effectiveness of cilostazol for serious events such as amputation, revascularisation, and cardiovascular events. Despite the importance of QoL to patients, meta‐analysis could not be undertaken because of differences in measures used and reporting. Very limited data indicated no difference between cilostazol and pentoxifylline for improving walking distance and data were too limited for any conclusions on other outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003748-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003748-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003748-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003748-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003748-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003748-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003748-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003748-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD003748-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003748-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003748-abs-0002" lang="en"> <h3>Cilostazol for peripheral arterial disease</h3> <p><b>Background</b> </p> <p>Blockages in the arteries to the legs ‐ peripheral arterial disease ‐ affect 20% of people aged over 70 years and 4% to 12% of people aged 55 to 70 years. Approximately 40% of those with peripheral arterial disease complain of pain in the legs or buttocks that occurs with exercise and subsides with rest. This is known as intermittent claudication and these symptoms are an indicator for the development of blocked arteries elsewhere in the body. People with intermittent claudication have a three‐ to six‐fold increased chance of dying as a result of cardiovascular events compared to people of the same age without intermittent claudication. </p> <p>People with intermittent claudication are treated with best medical management which includes modifying risk factors, such as stopping smoking, and doing structured exercise. Further cardiovascular risk modification includes treatment for high blood pressure, diabetes and cholesterol reduction. In practice, compliance with best medical treatment is poor and most people continue to have symptoms of intermittent claudication. Some drug therapies, such as cilostazol, are used to help improve symptoms of intermittent claudication and so we examined the evidence to see if cilostazol improved walking distance, quality of life and other important outcomes compared to placebo (dummy pill) or other drugs used for intermittent claudication. </p> <p><b>Study characteristics and key results</b> </p> <p>We included 16 double‐blind, randomised controlled trials, with 3972 adults (search up to 9 November 2020). Participants taking cilostazol for three to six months could walk approximately 26 metres further before calf pain and 40 metres further in total compared to participants taking placebo. However, participants taking cilostazol had nearly three times the odds of experiencing headache related to study medication. There is currently not enough information about the effectiveness of cilostazol for serious events such as amputation, revascularisation and cardiovascular events. Despite its importance, only four studies reported quality of life, using different tools and ways of reporting. Very limited data indicated no difference between cilostazol and pentoxifylline for improving walking distance, and there was not enough information comparing cilostazol with pentoxifylline, for any other outcomes. </p> <p><b>Certainty of the evidence</b> </p> <p>We judged the evidence to be 'very low' to 'low‐certainty' for all outcomes except headaches, which were 'moderate‐certainty'. All studies were downgraded because we strongly suspected publication bias from drug company involvement. </p> <p><b>Conclusion</b> </p> <p>Cilostazol can increase the distance walked both in total and before the onset of pain, compared to placebo. Cilostazol was associated with increased headaches and there was a lack of evidence for other important outcomes such as amputation, revascularisation and cardiovascular events. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003748-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003748-sec-0093"></div> <h3 class="title" id="CD003748-sec-0094">Implications for practice</h3> <section id="CD003748-sec-0094"> <p>Participants taking cilostazol for three to six months could walk approximately 26 metres further before the onset of calf pain and 40 metres further in terms of total distance on a treadmill compared to participants taking placebo. However, participants taking cilostazol had nearly three times the odds of experiencing headache compared to participants taking placebo. The value of these increases in walking distance will be patient‐specific. There is insufficient evidence about the effectiveness of cilostazol for serious events such as amputation, revascularisation, and cardiovascular events. Despite the importance of quality of life to patients, meta‐analysis could not be undertaken because of differences in measures used and how they were reported. </p> <p>Very limited data indicated no difference between cilostazol and pentoxifylline for improving walking distance, but the data were too limited to enable any meaningful conclusions to be drawn for any of the remaining outcomes reported. </p> <p>Using GRADE methods, we judged the evidence to be of very low to low certainty for all of the outcomes except for adverse events related to study medication where some events were judged as being at moderate certainty. All studies for both comparisons were downgraded one level because publication bias was strongly suspected. Other issues that necessitated downgrading included risk of selective reporting, imprecision and inconsistency. </p> </section> <h3 class="title" id="CD003748-sec-0095">Implications for research</h3> <section id="CD003748-sec-0095"> <p>Future research on cilostazol for the treatment of intermittent claudication should ideally be performed such that comparisons can be made with other studies. Currently, there is little consensus on treatment duration, treadmill test protocol, and outcome measurement/reporting, which inhibits direct comparisons. This is apparent in this review with the significant number of studies that could not be included in the meta‐analysis due to outcome reporting being inconsistent, and other variations making imputation inappropriate. Suggestions for future research include research that is independently funded and which directly compares cilostazol with other active drugs. Quality of life is extremely important to patients and needs to be measured as a matter of course and consistently in future studies, with agreement of which tools to use and how to report the data to enable comparison across studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003748-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003748-sec-0008"></div> <div class="table" id="CD003748-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cilostazol compared with placebo for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cilostazol compared with placebo for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> intermittent claudication<br/><b>Setting:</b> all outpatient settings<br/><b>Intervention:</b> cilostazol<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cilostazol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial claudication distance</b> </p> <p>(change in metres)</p> <p>12 to 24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in initial claudication distance was 32.28</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 26.49 higher<br/>(18.93 higher to 34.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1722<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p>(change in points/ percentage; COM, SF‐36, VascuQol, WIQ)</p> <p>16 to 24 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There appeared to be a general improvement of cilostazol over placebo across four studies that used the SF‐36 (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>). </p> <p>There were inconsistent results for walking impairment according to the WIQ (4 studies), three studies showed no difference between groups for walking impairment (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>) and one study reported a 20% increase in walking speed for the cilostazol group (<a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>). </p> <p>There were modest improvements across the domains of the COM in one study (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>). </p> <p>There was no difference between groups in one study using the VascuQol questionnaire (<a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1163</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meta‐analysis was not undertaken because of differences in measures used and how they were reported. See <a href="./full#CD003748-tbl-0002">Table 1</a> for further details. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Absolute claudication distance</b> </p> <p>(change in metres)</p> <p>12 to 24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in absolute claudication distance was 37.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 39.57 higher<br/>(21.8 higher to 57.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2360<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 4, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Arterial revascularisation</b> </p> <p>(number of cases)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.16<br/>(0.01 to 4.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>516<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Amputation</b> </p> <p>(number of cases)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.16<br/>(0.01 to 4.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>516<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event related to study medication ‐</b> </p> <p><b>headache</b> </p> <p>(number of cases)</p> <p>12 to 26 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.83<br/>(2.26 to 3.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2584<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2, 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000<br/>(210 to 295) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cardiovascular event</b> </p> <p>(number of cases)</p> <p>24 to 26 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 1.50<br/>(0.51 to 4.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>692<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000<br/>(8 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>COM:</b> Claudication Outcome Measure; <b>OR</b> : odds ratio; <b>SF‐36:</b> self‐administered Short‐form 36; <b>VascuQol:</b> Vascular Quality of Life; <b>WIQ:</b> Walking Impairment Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded by one level for risk of bias because 3 studies (<a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) rated at high risk for selective reporting </p> <p><sup>2</sup> downgraded by one level for publication bias because pharmaceutical sponsors involvement in most of these studies raises questions of whether unpublished studies that suggest no benefit exist </p> <p><sup>3</sup> downgraded by one level for imprecision because a range of quality of life measurement tools were used and results were reported in different ways (meta‐analysis was not undertaken for these reasons) </p> <p><sup>4</sup> downgraded by one level for risk of bias because 4 studies (<a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) rated at high risk for selective reporting </p> <p><sup>5</sup> downgraded by one level for inconsistency because of heterogeneity: I<sup>2</sup> = 72% cilostazol 100 mg twice daily versus placebo subgroup ‐ heterogeneity reduced to 0% when 2 studies removed (<a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>) </p> <p><sup>6</sup> downgraded by two levels for imprecision due to low number of participants and events from 1 RCT (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>) </p> <p><sup>7</sup> see <a href="./full#CD003748-tbl-0003">Table 2</a> for other adverse events related to study medication </p> <p><sup>8</sup> downgraded by one level for imprecision due to low number of participants and events from 2 RCTs (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003748-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Change in quality of life status (change in points or percentage from baseline)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). "><b>Beebe 1999</b> </a> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). "><b>Dawson 2000</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). "><b>Money 1998</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. "><b>O'Donnell 2009</b> </a> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg (n = 137)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 50 mg (n = 135)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n = 141)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg (n = 205)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pentox 400 mg (n = 212)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n = 226</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg (n = 119)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n =  120)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg ( n = 39)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n = 41)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Short‐form 36</b> (SF‐36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physical function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Role‐physical</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no improv</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no improv</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bodily pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Social function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Role‐emotional</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mental health</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General health</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Walking Impairment Questionnaire</b> (WIQ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walking speed</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walking distance</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>Claudication Outcome Measure</b> (COM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in pain/discomfort</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain/discomfort: daily activities</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain/discomfort: physical activities</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain/discomfort: social activities</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walking pain/discomfort</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worry/concern due to pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Vascular Quality of Life</b> (VascuQol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activity</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptom</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotion</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Social</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>diff: difference<br/>improv: improvement<br/>Pentox: pentoxifylline </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003748-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">2.</span> <span class="table-title">Adverse events related to study medication</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or pentoxifylline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cilostazol</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cilostazol compared to placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Diarrhoea</b> </p> <p>12 to 26 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.73<br/>(2.02 to 3.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2503<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000<br/>(108 to 181) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Abnormal stools</b> </p> <p>12 to 24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.63<br/>(2.45 to 5.38) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1804<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/>(101 to 198) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>12 to 26 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.42<br/>(1.43 to 4.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1120<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/>(60 to 153) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>12 to 24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.96<br/>(0.71 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1572<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/>(94 to 159) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Palpitations</b> </p> <p>24 to 26 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 7.16<br/>(3.95 to 12.98) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1681<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1, 3</sup> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 per 1000<br/>(60 to 173) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cilostazol compared to pentoxifylline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Diarrhoea</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 1.80<br/>(0.79 to 4.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>982<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1, 3, 4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162 per 1000<br/>(78 to 307) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Abnormal stools</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 3.12<br/>(1.57 to 6.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>459<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145 per 1000<br/>(79 to 253) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Pain</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 0.85<br/>(0.57 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>982<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 per 1000<br/>(74 to 151) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Palpitations</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 8.35<br/>(4.11 to 16.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>982<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134 per 1000<br/>(71 to 240) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> downgraded one level for publication bias because pharmaceutical sponsors involvement raises questions of whether unpublished studies that suggest no benefit exist </p> <p><sup>2</sup> downgraded one level for risk of bias because 2 studies (<a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) rated at high risk for selective reporting </p> <p>3 downgraded one level for imprecision due to wide CIs</p> <p>4 downgraded one level for inconsistency because of heterogeneity: I² = 77%</p> <p><sup>5</sup> downgraded one level for imprecision due to data from 1 RCT with wide CIs (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003748-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cilostazol compared with pentoxifylline for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cilostazol 100 mg twice daily compared with pentoxifylline 400 mg twice daily for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> intermittent claudication<br/><b>Setting:</b> all outpatient settings<br/><b>Intervention:</b> cilostazol 100 mg twice daily<br/><b>Comparison:</b> pentoxifylline 400 mg three times daily </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pentoxifylline 400 mg twice daily</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cilostazol 100 mg twice daily</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial claudication distance</b> </p> <p>(change in meters)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in initial claudication distance was 73.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20.00 higher<br/>(2.57 lower to 42.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p>(change in points, SF‐36, WIQ)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quote "None of the treatments significantly affected the Medical Outcomes Scale Short Form‐36 scores on Mental Health Concepts, General Health Perception, Physical Health Concepts, or Vitality Scores. There were also no<br/>significant differences in patient‐reported walking distance or speed as determined by the Walking Impairment Questionnaire." (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>317</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Absolute claudication distance</b> </p> <p>(change in metres)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in absolute claudication distance was 70.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 13.43 higher<br/>(43.50 lower to 70.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>866<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 4, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arterial revascularisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amputation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event related to study medication ‐ headache</b> </p> <p>(number of cases)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.20<br/>(1.16 to 4.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>982<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/>(127 to 343) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>SF‐36:</b> self‐administered Short‐form 36; <b>WIQ:</b> Walking Impairment Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one level for imprecision because 1 RCT had a low number of participants (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>) </p> <p><sup>2</sup> downgraded one level because publication bias strongly suspected </p> <p><sup>3</sup> downgraded by two levels for imprecision because 1 RCT had a low number of participants (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>) and imprecision could not be evaluated </p> <p><sup>4</sup> downgraded one level for inconsistency because of heterogeneity: I<sup>2 </sup>≥ 50% </p> <p><sup>5</sup> downgraded one level for imprecision due to very wide CIs </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003748-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003748-sec-0009"></div> <section id="CD003748-sec-0010"> <h3 class="title" id="CD003748-sec-0010">Description of the condition</h3> <p>Lower limb peripheral arterial disease (PAD) is a manifestation of atherosclerosis in the lower extremities, affecting 20% of people over 70 years of age and 4% to 12% of the population aged 55 to 70 years (<a href="./references#CD003748-bbs2-0056" title="DormandyJ , HeeckL , VigS . The natural history of claudication: risk to life and limb. Seminars in Vascular Surgery1999;12(2):123-37.">Dormandy 1999</a>; <a href="./references#CD003748-bbs2-0073" title="Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. European Journal of Vascular and Endovascular Surgery2003;26(1):1-16.">PAD 2003</a>). Patients with PAD commonly complain of intermittent claudication, which is characterised by pain in the legs or buttocks that occurs with exercise and subsides with rest, and occurs in 40% of PAD patients (<a href="./references#CD003748-bbs2-0056" title="DormandyJ , HeeckL , VigS . The natural history of claudication: risk to life and limb. Seminars in Vascular Surgery1999;12(2):123-37.">Dormandy 1999</a>). Despite the relatively benign prognosis for the affected limb, the symptoms of intermittent claudication are an indicator for systemic atherosclerosis. Compared with age‐matched controls, people with intermittent claudication have a three‐ to six‐fold increase in cardiovascular mortality (<a href="./references#CD003748-bbs2-0069" title="LengGC , LeeAJ , FowkesFG , WhitemanM , DunbarJ , HousleyE , et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral artery disease in the general population. International Journal of Epidemiology1996;25(6):1172-81.">Leng 1996</a>). About 4% of people with intermittent claudication will require amputation over five years of follow‐up (<a href="./references#CD003748-bbs2-0069" title="LengGC , LeeAJ , FowkesFG , WhitemanM , DunbarJ , HousleyE , et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral artery disease in the general population. International Journal of Epidemiology1996;25(6):1172-81.">Leng 1996</a>). </p> <p>The majority of patients with intermittent claudication are treated with best medical treatment (<a href="./references#CD003748-bbs2-0065" title="KhanS , CleanthisM , SmoutJ , FlatherM , StansbyG . Life-style modification in peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2005;29(1):2-9.">Khan 2005</a>), and the mainstay of treatment for patients with PAD is cardiovascular risk factor modification. This consists of smoking cessation, prescribed exercise (<a href="./references#CD003748-bbs2-0066" title="LaneR , HarwoodA , WatsonL , Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews2017, Issue 12. Art. No: CD000990. [DOI: 10.1002/14651858.CD000990.pub4]">Lane 2017</a>), antiplatelet treatment, lipid‐lowering therapy and control of blood pressure and diabetes. Only two‐thirds of compliant patients will achieve symptomatic relief of intermittent claudication after three to six months. Some patients may not be able to comply with prescribed exercise due to associated comorbidity or social reasons. As angioplasty or surgery are only used in severe, disabling or progressive intermittent claudication, these symptomatic patients may benefit from adjunctive therapy. </p> </section> <section id="CD003748-sec-0011"> <h3 class="title" id="CD003748-sec-0011">Description of the intervention</h3> <p>Cilostazol, with the trade name Pletal, is a phosphodiesterase‐III inhibitor that has antiplatelet and antithrombotic actions (<a href="./references#CD003748-bbs2-0078" title="SallustioF , RotondoF , Di LeggeS , StanzioneP . Cilostazol in the management of atherosclerosis. Current Vascular Pharmacology2010;8(3):363-72.">Sallustio 2010</a>). Cilostazol also acts on smooth muscle cells as a vasodilator with beneficial effects on triglycerides and high‐density lipoproteins (<a href="./references#CD003748-bbs2-0053" title="ChapmanTM , GoaKL . Cilostazol: a review of its use in intermittent claudication. American Journal of Cardiovascular Drugs2003;3(2):117-38.">Chapman 2003</a>). Cilostazol is indicated for intermittent claudication but there is also evidence to suggest that cilostazol may have a role in reducing restenosis after endovascular therapy and coronary stenting (<a href="./references#CD003748-bbs2-0064" title="IidaO , NantoS , UematsuM , MorozumiT , KitakazeM , NagataS . Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. Journal of Vascular Surgery2008;48(1):144-9.">Iida 2008</a>; <a href="./references#CD003748-bbs2-0067" title="LeeSW , AhnJM , HanS , ParkGM , ChoYR , LeeWS , et al. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials). American Journal of Cardiology2013;112(9):1328-34.">Lee 2013</a>). The suggested dose of cilostazol for intermittent claudication is 100 mg taken orally twice daily. Cilostazol is contraindicated in patients with congestive heart failure and those with renal or hepatic impairment (<a href="./references#CD003748-bbs2-0053" title="ChapmanTM , GoaKL . Cilostazol: a review of its use in intermittent claudication. American Journal of Cardiovascular Drugs2003;3(2):117-38.">Chapman 2003</a>; <a href="./references#CD003748-bbs2-0055" title="DawsonDL . Comparative effects of cilostazol and other therapies for intermittent claudication. American Journal of Cardiology2001;87(12A):19D-27D.">Dawson 2001</a>). </p> </section> <section id="CD003748-sec-0012"> <h3 class="title" id="CD003748-sec-0012">How the intervention might work</h3> <p>Antiplatelet therapy is effective in long‐term secondary prevention of vascular events in patients at high risk of vascular disease, including those who have had ischaemic stroke or acute myocardial infarction, and a benefit of antiplatelet treatment in patients with intermittent claudication in the reduction of vascular events has been previously observed (<a href="./references#CD003748-bbs2-0050" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002;324(7329):71-86.">ATT 2002</a>; <a href="./references#CD003748-bbs2-0072" title="NiuPP , GuoZN , JinH , XingYQ , YangY . Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ Open2016;6(3):e009013. [DOI: 10.1136/bmjopen-2015-009013]">Niu 2016</a>; <a href="./references#CD003748-bbs2-0073" title="Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. European Journal of Vascular and Endovascular Surgery2003;26(1):1-16.">PAD 2003</a>; <a href="./references#CD003748-bbs2-0077" title="RoblessP , MikhailidisD , StansbyG . Systematic review of antiplatelet therapy for prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. British Journal of Surgery2001;88(6):787-800.">Robless 2001</a>). It is unclear exactly how cilostazol works to improve claudication, but the mechanism is most likely multifactorial, involved with several of cilostazol's actions, specifically vasodilation, possible beneficial inhibition of platelet aggregation, and altering a patient's lipid profile (<a href="./references#CD003748-bbs2-0053" title="ChapmanTM , GoaKL . Cilostazol: a review of its use in intermittent claudication. American Journal of Cardiovascular Drugs2003;3(2):117-38.">Chapman 2003</a>; <a href="./references#CD003748-bbs2-0076" title="RizzoM , CorradoE , PattiAM , RiniGB , MikhailidisDP . Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?Expert Opinion on Pharmacotherapy2011;12(4):647-55.">Rizzo 2011</a>; <a href="./references#CD003748-bbs2-0084" title="UenoH , KoyamaH , MimaY , FukumotoS , TanakaS , ShojiT , et al. Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. Journal of Atherosclerosis and Thrombosis2011;18(10):883-90.">Ueno 2011</a>). </p> </section> <section id="CD003748-sec-0013"> <h3 class="title" id="CD003748-sec-0013">Why it is important to do this review</h3> <p>Treatment of intermittent claudication includes best medical treatment (BMT), lifestyle changes, physical exercise and angioplasty, if appropriate (<a href="./references#CD003748-bbs2-0060" title="HaileS , LinnéA , JohanssonUB , Joelsson-AlmE . Follow-up after surgical treatment for intermittent claudication (FASTIC): a study protocol for a multicentre randomised controlled clinical trial. BMC Nursing2020;19(45):1-12. [DOI: 10.1186/s12912-020-00437-7]">Haile 2020</a>). A recent review demonstrated that angioplasty and supervised exercise were 'more or less comparable treatment options' (<a href="./references#CD003748-bbs2-0057" title="FakhryF , FokkenroodHJP , SpronkS , TeijinkJAW , RouwetEV , HuninkMGM . Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database of Systematic Reviews2018, Issue 3. Art. No: CD010512. [DOI: 10.1002/14651858.CD010512.pub2]">Fakhry 2018</a>). In practice, compliance with BMT is poor and most people remain symptomatic with intermittent claudication. There are various pharmacological agents, as well as cilostazol, used in the treatment of intermittent claudication including anticoagulants (<a href="./references#CD003748-bbs2-0054" title="CosmiB , ContiE , CoccheriS . Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD001999. [DOI: 10.1002/14651858.CD001999.pub2]">Cosmi 2014</a>), antiplatelets (<a href="./references#CD003748-bbs2-0085" title="WongPF , ChongLY , MikhailidisDP , RoblessP , StansbyG . Antiplatelet agents for intermittent claudication. Cochrane Database of Systematic Reviews2011, Issue 11. Art. No: CD001272. [DOI: 10.1002/14651858.CD001272.pub2]">Wong 2011</a>), and pentoxifylline (<a href="./references#CD003748-bbs2-0052" title="BroderickC , ForsterR , Abdel-HadiM , SalhiyyahK . Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262.pub4]">Broderick 2020</a>). However, there is a degree of uncertainty as to which, if any, of these medications provides the most clinical benefit. The National Institute for Health and Care Excellence (NICE) (clinical guideline 147, last updated December 2020), recommends the use of naftidrofuryl for people with intermittent claudication caused by PAD; cilostazol is licensed for the treatment of PAD in selected patients who do not respond to other treatments (<a href="./references#CD003748-bbs2-0071" title="National Institute for Health and Care Excellence (NICE). Peripheral arterial disease: diagnosis and management (last updated December 2020). nice.org.uk/Guidance/CG147 (accessed 12 March 2021).">NICE 2012</a>). NICE clinical guidelines are underpinned by cost‐effectiveness analysis which is outside the remit of this review. If cilostazol is found to reduce the symptoms of claudication, as well as cardiovascular risk in patients with PAD, it would offer some patients another clinical option. This is an update of the review first published in 2007 (<a href="./references#CD003748-bbs2-0087" title="RoblessP , MikhailidisDP , StansbyGP . Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD003748. [DOI: 10.1002/14651858.CD003748.pub2]">Robless 2007</a>) and incorporates the most recent literature and advances in Cochrane methodology, with respect to grading of the evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003748-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003748-sec-0014"></div> <p>To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003748-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003748-sec-0015"></div> <section id="CD003748-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003748-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included double‐blind, randomised controlled trials of cilostazol versus placebo, or versus other drugs used to improve claudication distance. </p> </section> <section id="CD003748-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants with stable intermittent claudication (determined by a physician or investigator). We excluded studies that identified their participants as those with peripheral arterial disease (PAD), atherosclerosis obliterans, or similar, but did not specifically state that their study population had intermittent claudication. </p> </section> <section id="CD003748-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared cilostazol versus placebo, or other drugs used to improve claudication distance, e.g. pentoxifylline. The interventions must have been given for at least four weeks. We excluded comparisons with exercise, anticoagulants or surgery. </p> </section> <section id="CD003748-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD003748-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003748-list-0001"> <li> <p>Initial claudication distance (ICD) (the distance walked on a treadmill before the onset of calf pain) </p> </li> <li> <p>Health‐related quality of life (QoL), including general and disease‐specific QoL, measured by a validated questionnaire </p> </li> </ul> </p> </section> <section id="CD003748-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003748-list-0002"> <li> <p>Absolute claudication distance (ACD) (the maximum distance walked on a treadmill)</p> </li> <li> <p>Revascularisation (angioplasty or surgical bypass)</p> </li> <li> <p>Amputation</p> </li> <li> <p>Adverse events related to study medication</p> </li> <li> <p>Cardiovascular events (defined as stroke, unstable angina, acute myocardial infarction (MI)) </p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Ankle brachial index (ABI)</p> </li> <li> <p>Major Adverse Limb Event (MALE) defined as major vascular amputation or any vascular re‐intervention, including surgical or endovascular re‐intervention </p> </li> </ul> </p> </section> </section> </section> <section id="CD003748-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003748-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for randomised controlled trials and controlled clinical trials without language, publication year or publication status restrictions. </p> <p> <ul id="CD003748-list-0003"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web searched from inception to 10 November 2020). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO 2020, Issue 10). </p> </li> <li> <p>MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE® 1946 to present) (searched 9 November 2020). </p> </li> <li> <p>Embase Ovid (searched 9 November 2020).</p> </li> <li> <p>CINAHL Ebsco (searched 9 November 2020).</p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for other databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6, <a href="./references#CD003748-bbs2-0068" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD003748-sec-0099">Appendix 1</a>.<br/>The information Specialist also searched the following trials registries on 10 November 2020. </p> <p> <ul id="CD003748-list-0004"> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>) </p> </li> <li> <p><a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> </p> </li> </ul> </p> </section> <section id="CD003748-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of relevant articles retrieved by the electronic searches, for additional citations. </p> </section> </section> <section id="CD003748-sec-0026"> <h3 class="title" id="CD003748-sec-0026">Data collection and analysis</h3> <section id="CD003748-sec-0027"> <h4 class="title">Selection of studies</h4> <p>For this update, two review authors (TB and MS), independently evaluated studies for inclusion based on selection criteria. Disagreements were resolved by discussion between the two review authors. </p> </section> <section id="CD003748-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For this update, two review authors (TB and RBF), independently extracted the data. We identified one new eligible study for this update. We collected information regarding the trial design, participant characteristics, therapy type, dosages and treatment periods. We collected information for the primary outcomes of ICD and QoL and secondary outcomes including ACD, revascularisation, amputation, adverse events, cardiovascular events, all‐cause mortality, and ABI. We resolved disagreements through discussion between the two review authors. Data were entered into and analysed using Review Manager (<a href="./references#CD003748-bbs2-0075" title="The Cochrane CollaborationReview Manager Web (RevMan Web). The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2019</a>). </p> </section> <section id="CD003748-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this update, two review authors (TB and RBF), independently assessed the methodological quality using Cochrane's risk of bias tool (<a href="./references#CD003748-bbs2-0061" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). We assessed the following domains: selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting) and other bias. We classified the domains as low risk, high risk, or unclear risk of bias, according to the guidelines in <a href="./references#CD003748-bbs2-0061" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>. Disagreements were resolved by discussion between the two review authors. </p> </section> <section id="CD003748-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We pooled the data on ICD, ACD and ABI, to obtain an overall estimate of the effectiveness of cilostazol therapy. We used mean change from baseline for each trial, which is more informative of treatment effect than simply comparing final walking distances because it takes baseline measures into account. Due to the differences in treadmill testing methods between the studies, mean change from baseline is the only appropriate measure for treatment effect. The results for continuous data are presented as mean differences (MDs) with 95% confidence intervals (CIs), and dichotomous data as odds ratios (ORs) with 95% CIs. </p> </section> <section id="CD003748-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant in all studies included in this review. For studies with more than two treatment arms of relevance to the same meta‐analysis and with one control arm, we included data from both treatment arms. To avoid double counting of participants, we halved the number of participants in the control arm. For dichotomous outcomes, both the number of events and the total number of participants were divided up. For continuous outcomes only the total number of participants was divided up (means and standard deviations remained unchanged). This method only partially overcomes the unit of analysis error because the resulting comparisons remain correlated (<a href="./references#CD003748-bbs2-0063" title="Higgins JPT , Eldridge S, LiT . Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021a</a>). However, we were interested in evaluating all doses of drug intervention as well as drug interventions per se, so we did not feel it was appropriate to pool the intervention group data within each study. </p> </section> <section id="CD003748-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>In previous versions of the review, when data were not available or missing, study authors were contacted to request missing data. Data imputation was not carried out and reasons for study data not being included in meta‐analyses were recorded (<a href="#CD003748-tbl-0005">Table 3</a>). All of the analyses were based on the number of participants accessed for each outcome within each study. </p> <div class="table" id="CD003748-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reasons for study not being included in meta‐analyses of initial claudication distance (ICD), absolute claudication distance (ACD) and ankle brachial index (ABI)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reason for data not included in ICD, ACD or ABI outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in peak walking time and initial claudication time with SDs, but the treadmill method was not clear, so we could not reliably convert from time to distance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes of interest were only broken down between non‐smokers and smokers, but not between treatment groups. Figures 2 and 3 do offer graphical information on the mean change in maximal walking distances, 'expressed as percent of control'. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For ACD and ABI, mean baseline and follow‐up values with SD were given; we can calculate mean change but for the imputation of SD we need the SDs associated with the change and the baseline and the post‐intervention mean, for at least one similar length study, which we do not have. Mean changes in ACD without SD or other variance were also reported in the text. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For ICD and ACD, mean baseline and follow‐up values were given, but no SDs were given. A P value was given for the overall treatment effect but that was for the comparison between cilostazol and placebo, not between baseline and follow‐up. For ABI only, interquartile ranges were given, which could not be adequately converted to SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo‐corrected mean change from baseline was provided for the treatment group, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and placebo, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw mean change from baseline was provided for the cilostazol and placebo groups, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and placebo, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo‐corrected mean change from baseline was provided for the treatment group, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and placebo, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the ICD outcome, only a ratio of the geometric means of change was calculated between cilostazol and the comparison, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For ICD, raw mean change from baseline was provided for the cilostazol and comparison groups, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and comparisons, but these data could not be recalculated to mean change and SD. Mean change data with SDs were available for the ACD outcome. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACD: absolute claudication distance<br/>ABI: ankle brachial index<br/>ICD: initial claudication distance<br/>SD: standard deviation </p> </div> </div> </section> <section id="CD003748-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated trial heterogeneity using Chi<sup>2</sup> and I<sup>2</sup> testing, which describe the variability in effect estimates that are due to heterogeneity between studies, rather than chance. The I<sup>2</sup> is given as a percentage, with a measure of 0% meaning little to no variability in effect estimates between the studies, and progressing amounts of variability with increased I<sup>2</sup> percentage values (<a href="./references#CD003748-bbs2-0062" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). If tests for heterogeneity found I<sup>2</sup> &gt; 50%, we planned to use a random‐effects model, otherwise, we planned to use a fixed‐effect model.  We are aware there can be uncertainty around the value of  I<sup>2</sup> and using thresholds for interpretation, and so we also considered the direction and magnitude of effects and degree of overlap between CIs. </p> </section> <section id="CD003748-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We hoped to assess reporting bias by funnel plots if more than ten studies were included in the meta‐analysis (<a href="./references#CD003748-bbs2-0062" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>).  As we did not include more than ten studies in any analysis, we did not do this. </p> </section> <section id="CD003748-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We used a pooled fixed‐effect model meta‐analysis with subgrouping, where appropriate. We used a random‐effects model when tests for heterogeneity found I<sup>2</sup> &gt; 50%. We also considered the direction and magnitude of effects and degree of overlap between CI. For outcomes where we were unable to pool data, we described the results narratively. </p> </section> <section id="CD003748-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For this update, we synthesised the data by drug comparison and so it was appropriate to subgroup by drug dose. </p> </section> <section id="CD003748-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>In order to determine that robust conclusions could be drawn using meta‐analyses, we removed studies of a lower methodological quality (defined as studies with five or more high‐risk or unclear‐risk ratings within the seven domains evaluated for risk of bias), from the analysis to determine the effect on the association. We planned to undertake sensitivity analysis only if sufficient studies remained in the analyses to provide a meaningful result. </p> </section> <section id="CD003748-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>For this update, we prepared a summary of findings table to present the findings from our review for the comparisons 'Cilostazol versus placebo' (<a href="./full#CD003748-tbl-0001">summary of findings Table 1</a>) and 'Cilostazol versus pentoxifylline' (<a href="./full#CD003748-tbl-0004">summary of findings Table 2</a>), using GRADEpro software (<a href="./references#CD003748-bbs2-0059" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 14 January 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro</a>). We used the GRADE method, to evaluate the evidence based on the risk of bias of the individual studies, inconsistency, imprecision, indirectness and publication bias (<a href="./references#CD003748-bbs2-0079" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). We evaluated the following outcomes because they were the most clinically relevant: </p> <p> <ul id="CD003748-list-0005"> <li> <p>ICD</p> </li> <li> <p>health‐related QoL</p> </li> <li> <p>ACD</p> </li> <li> <p>revascularisation</p> </li> <li> <p>amputation</p> </li> <li> <p>adverse events related to study medication ‐ headache</p> </li> <li> <p>cardiovascular events</p> </li> </ul> </p> <p>Where meta‐analysis was not undertaken, we described the evidence using a narrative approach. GRADE assessments for the other outcomes of adverse events that were not included in the summary of findings tables are presented in an additional table (<a href="./full#CD003748-tbl-0003">Table 2</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003748-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003748-sec-0039"></div> <section id="CD003748-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD003748-sec-0041"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD003748-fig-0001">Figure 1</a>. For this update of the review, we identified one new study (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>), one additional report of a previously included study (<a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>), and one study is awaiting classification (<a href="./references#CD003748-bbs2-0048" title="SapelkinSV , KharazovAF . Advanced position in the conservative treatment of patients with peripheral arterial disease. Khirurgiia2013;4:68-73. ">Sapelkin 2013</a>). We excluded 23 new studies. This review update involved a total of 16 included studies and 31 excluded studies. </p> <div class="figure" id="CD003748-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003748-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003748-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD003748-sec-0114" title="">Characteristics of included studies</a> for more detail. We included 16 studies with 3972 participants. Treatment duration ranged between six and 26 weeks. All participants had intermittent claudication secondary to peripheral arterial disease (PAD). All included studies compared cilostazol 100 mg twice daily with placebo. Two studies also compared cilostazol 50 mg twice daily with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) and one study compared cilostazol 150 mg twice daily with placebo (<a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>). Three studies also compared cilostazol 100 mg twice daily with pentoxifylline 400 mg three times daily (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>), one study compared cilostazol 100 mg twice daily with pentoxifylline 600 mg twice daily (<a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>) and one study compared cilostazol 100 mg twice daily with pentoxifylline 400 mg twice daily (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>). <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> had treatment groups excluded from our analyses (K‐134, 50 mg and 100 mg twice daily) because K‐134 is not an alternative antiplatelet agent or medication currently known to increase walking distance. </p> <p>Seven studies were published in journal articles and six studies were not published as journal articles, with sources of data being a medical review by the FDA in five cases (<a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>), and a pharmaceutical submission to NICE in the other case (<a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). All 16 studies received funding from pharmaceutical companies, 13 of which received funding from Otsuka Pharmaceuticals, the company that formulated cilostazol. <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> was the only study to report a declaration of interest (no conflicts declared). Five studies had study authors employed by a pharmaceutical company; including Otsuka Pharmaceuticals in four cases (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>), and Kowa Research Institute in another case (<a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>). One study (<a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>), reported that a study author received financial support from Otsuka Pharmaceuticals for travel costs to attend conferences to present data from the trial. </p> <p>For two studies, the duration of treatment was six weeks (<a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>), and for one study the treatment duration was eight weeks (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>). Four studies had a treatment duration of 12 weeks (<a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>), and one study treated participants for 16 weeks (<a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>). The <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> study had a treatment period of 20 weeks. The most common treatment duration was 24 weeks, in six studies (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>), and one study had a treatment duration of 26 weeks (<a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>). The number of participants in each study ranged from 19 in <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a> to 780 in <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>. </p> <p>For the walking distance outcomes (initial claudication distance (ICD) and absolute claudication distance (ACD)), the treadmill test methods varied between three protocols. Five studies used a method with an immediate and constant gradient of 10% and a constant speed of 3.2 km/h (<a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>; <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>). Six studies used a similar method with an immediate and constant gradient of 12.5% and a constant speed of 3.2 km/h (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). Four studies adopted a delayed gradient treadmill method where the gradient began at 0% and increased by 3.5% every three minutes, with a constant speed of 3.2 km/h (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>). It should be noted that the <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> study did not state the gradient by which the treadmill was increased, but it was assumed to be similar to the other three studies. The <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> study only described their treadmill method as "graded" and referred to another study, but we were unable to determine from this which method was used. </p> </section> <section id="CD003748-sec-0043"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD003748-sec-0115" title="">Characteristics of excluded studies</a> for more detail. </p> <p>Studies that were not RCTs or were not double‐blinded were judged not relevant. For this update, we excluded 23 new studies making a total of 31 excluded studies. There were nine previously excluded studies; one of these was non‐randomised and was removed from the list of studies excluded with reasons. </p> <p>Briefly, 15 studies included the wrong patient population (<a href="./references#CD003748-bbs2-0018" title="ChaoTH , TsengSY , ChenIC , TsaiYS , HuangYY , LiuPY , et al. Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. International Journal of Cardiology2014;172(2):e371-4. [DOI: 10.1016/j.ijcard.2013.12.295]">Chao 2014</a>; <a href="./references#CD003748-bbs2-0019" title="ChaoTH , ChenIC , LeeCH , ChenJY , TsaiWC , LiYH , et al. Cilostazol enhances mobilization of circulating endothelial progenitor cells and improves endothelium-dependent function in patients at high risk of cardiovascular disease. Angiology2016;67(7):638-46. [DOI: 10.1177/0003319715606249]ChaoTH , ChenIC , LiuPY , TsaiWC , LiYH , TsengSY , et al. Cilostazol enhances mobilization of circulating endothelial progenitor cells and improves endothelium-dependent function mediated by modifying metabolic and angiogenic markers in patients with high risk for cardiovascular disease. Journal of the American College of Cardiology2015;65(10):A1650. ChaoTH , LiuPY , TsaiWC , TsengSY , LiYH . The vasculo-angiogenic and vaso-protective effects of cilostazol in patients with high risk for cardiovascular disease. European Heart Journal2015;36(Suppl 1):229. [DOI: 10.1093/eurheartj/ehv399]ChaoTH , TsengSY , TsaiYS , HuangYY , LiuPY , OuHY , et al. Cilostazol enhances mobilization and proliferation of circulating endothelial progenitor cells and collateral formation mediated by modifying vasculo-angiogenic biomarkers in patients with peripheral arterial occlusive disease. Journal of the American College of Cardiology2013;61(10):E2052. [DOI: http://dx.doi.org/10.1016/S0735-1097%2813%2962052-5]">Chao 2016</a>; <a href="./references#CD003748-bbs2-0020" title="ChaoTH , LiYH , TsengSY , LiuPY . The associations between the effect of cilostazol on the proprotein convertase subtilisin/kexin type 9 concentrations and circulating endothelial progenitor cells and vasculo-angiogenesis factors. European Heart Journal2018;39(Suppl 1):523. [DOI: 10.1093/eurheartj/ehy565.P2620]ChenIC , TsengWK , LiYH , TsengSY , LiuPY , ChaoTH . Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget2017;8(64):108042-53. ">Chen 2017</a>; <a href="./references#CD003748-bbs2-0021" title="ChiCTR-TRC-09000441. Evaluation of efficacy of cilostazol on type 2 diabetes with ischemic disease of lower extremity by transcutaneous oxygen pressure measurement. who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-09000441 (retrospectively registered 24 June 2009). ">ChiCTR‐TRC‐09000441</a>; <a href="./references#CD003748-bbs2-0022" title="ChisariLM , MalaguarneraS , GrassoA , MalaguarneraM , ChisariG , BorzìAM , et al. Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease. La Clinica Terapeutica2019;170(5):e357-63. [DOI: 10.7417/CT.2019.2160]">Chisari 2019</a>; <a href="./references#CD003748-bbs2-0024" title="HsiehCJ , WangPW . Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circulation Journal2009;73(5):948-54. ">Hsieh 2009</a>; <a href="./references#CD003748-bbs2-0025" title="JPRN-C000000215. Study on therapeutic effects of antiplatelet drugs in prevention of occurrence and inhibition of progression of diabetic atherosclerosis. who.int/trialsearch/Trial2.aspx?TrialID=JPRN-C000000215 (first posted 2005). ">JPRN‐C000000215</a>; <a href="./references#CD003748-bbs2-0026" title="JPRN-UMIN000001198. Cilostazol trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000001198 (first posted 20 June 2008). ">JPRN‐UMIN000001198</a>; <a href="./references#CD003748-bbs2-0029" title="KimNH , KimHY , AnH , SeoJA , KimNH , ChoiKM , et al. Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial. Diabetology and Metabolic Syndrome2013;5(1):41. ">Kim 2013</a>; <a href="./references#CD003748-bbs2-0034" title="NCT00573950. Effects of cilostazol on plasma adipocytokine and arterial stiffness. clinicaltrials.gov/show/NCT00573950 (first posted 14 December 2007). ">NCT00573950</a>; <a href="./references#CD003748-bbs2-0035" title="NCT00886574. Cilostazol versus aspirin for primary prevention of atherosclerotic events (CAPPA). clinicaltrials.gov/show/NCT00886574 (first posted 22 April 2009). ">NCT00886574</a>; <a href="./references#CD003748-bbs2-0036" title="NCT00912756. Sufficient treatment of peripheral intervention by cilostazol (STOP-IC). clinicaltrials.gov/ct2/show/NCT00912756 (first posted 2 June 2009). ">NCT00912756</a>; <a href="./references#CD003748-bbs2-0038" title="NCT01952756. Effect of cilostazol endothelial progenitor cells and collateral formation in peripheral occlusive artery disease (PAOD). clinicaltrials.gov/show/NCT01952756 (first posted 21 September 2013). ">NCT01952756</a>; <a href="./references#CD003748-bbs2-0037" title="NCT01188824. The safety and efficacy of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD study). clinicaltrials.gov/ct2/show/NCT01188824 (first posted 26 August 2010). ">NCT01188824</a>; <a href="./references#CD003748-bbs2-0047" title="XiaoZ , ChenL , YangC , YangH , LuoB , MaiL , et al. Evaluation of cilostazol efficacy on type 2 diabetes with lower limb ischemic disease by transcutaneous oxygen pressure measurement. In: American Diabetes Association. 70th Scientific Sessions; 2010. Guangdong, China (professional.diabetes.org/abstract/evaluation-cilostazol-efficacy-type-2-diabetes-lower-limb-ischemic-disease-transcutaneous): American Diabetes Association, 2010 (accessed 1 April 2021). ">Xiao 2010</a>). Eleven studies were excluded due to the wrong intervention, for example, iloprost, olmesarten, sildenafil, ticagrelor and valsarten (<a href="./references#CD003748-bbs2-0023" title="GoldenbergNA , KrantzMJ , HiattWR . L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vascular Medicine2012;17(3):145-54. [DOI: 10.1177/1358863X12442264]">Goldenberg 2012</a>; <a href="./references#CD003748-bbs2-0027" title="JPRN-UMIN000011869. Relationship between arteriosclerosis obliterans and serum level of eicosapentaenoic acid as prospective interventional study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000011869 (first posted 26 September 2013). ">JPRN‐UMIN000011869</a>; <a href="./references#CD003748-bbs2-0028" title="JPRN-UMIN000014307. Phase IIb double blinded parallel group dose response study for DVC1-0101 to treat severe intermittent claudication. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014307 (first posted 1 September 2014). ">JPRN‐UMIN000014307</a>; <a href="./references#CD003748-bbs2-0030" title="MazzoneA , Di SalvoM , MazzucaS , ValerioA , GussoniG , BonizzoniE , et al. Effects of iloprost on pain-free walking distance and clinical outcome in patients with severe stage IIb peripheral arterial disease: the FADOI 2b PILOT Study. European Journal of Clinical Investigation2013;43(11):1163-70. [DOI: 10.1111/eci.12159]">Mazzone 2013</a>; <a href="./references#CD003748-bbs2-0031" title="NCT00102050. Efficacy and safety of NM-702 tablets for the treatment of intermittent claudication. clinicaltrials.gov/show/NCT00102050 (first received 19 January 2005). ">NCT00102050</a>; <a href="./references#CD003748-bbs2-0039" title="NCT02373462. Effect of olmesaRtan on walking distancE and quaLIty of lifE in peripheral artery disease patients with hypertension treated for intermittent claudication (RELIEF). clinicaltrials.gov/show/NCT02373462 (first posted 14 February 2015). ">NCT02373462</a>; <a href="./references#CD003748-bbs2-0040" title="NCT02407314. Ticagrelor and peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT02407314 (first posted 18 March 2015). ">NCT02407314</a>; <a href="./references#CD003748-bbs2-0041" title="NCT02636283. Use of entresto sacubitril/valsartan for the treatment of peripheral arterial disease. clinicaltrials.gov/show/NCT02636283 (first posted 29 October 2015). ">NCT02636283</a>; <a href="./references#CD003748-bbs2-0042" title="NCT02930811. Efficacy of sildenafil on the morbi-mortality of peripheral arterial diseased patients with intermittent claudication (VALSTAR). clinicaltrials.gov/show/NCT02930811 (first posted 10 October 2016). ">NCT02930811</a>; <a href="./references#CD003748-bbs2-0043" title="NCT03318276. Clinical trial to evaluate efficacy and safety of SID142 in patients with chronic artery occlusive disease. clinicaltrials.gov/show/NCT03318276 (first posted 18 October 2017). ">NCT03318276</a>; <a href="./references#CD003748-bbs2-0044" title="NCT03686306. VIRTUOSE: efficiency of sildenafil on the absolute claudication distance of peripheral arterial disease patients with intermittent claudication (VIRTUOSE). clinicalTrials.gov/show/NCT03686306 (first posted 24 September 2018). ">NCT03686306</a>). We excluded the <a href="./references#CD003748-bbs2-0033" title="NCT00443287. Efficacy and safety of HMR1766 in patients with Fontaine Stage II peripheral arterial disease. www.clinicaltrials.gov/ct2/show/NCT00443287 (first posted 5 March 2007). ">NCT00443287</a> study because the intervention arms were not clear, and we were unable to determine if clopidogrel was also used. We excluded one study because the duration of follow‐up far exceeded that of the other included studies, and follow‐up data at earlier time points were not available (<a href="./references#CD003748-bbs2-0017" title="HiattWR , MoneySR , BrassEP . Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects). Journal of Vascular Surgery2008;47(2):330-6. Otsuka 21-98-214-01. CASTLE. A randomized, double-blind, placebo-controlled, multicenter, parallel-arm, study to assess the long-term effects of Pletal® (Cilostazol) versus placebo administered orally to patients with intermittent claudication secondary to peripheral arterial disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). StoneWM , DemaerschalkBM , FowlRJ , MoneySR . Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. Journal of Stroke and Cerebrovascular Diseases2008;17(3):129-33. StoneWM , FowlRJ , MoneySR . Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. In: Vascular Annual Meeting; 2007 Jun 6-10; Baltimore. 2007. ">CASTLE 2008</a>). The <a href="./references#CD003748-bbs2-0032" title="NCT00300339. MASCOT: mixed antagonist of serotonin for claudication optimal therapy. clinicaltrials.gov/ct2/show/NCT00300339 (first received 8 March 2006). ">NCT00300339</a> study was discontinued early, and no outcome data were available for the trial. We were unable to determine if the <a href="./references#CD003748-bbs2-0045" title="Otsuka America. Pletal (Cilostazol) Tablets. Study PUIC-1. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study PUIC‐1</a> was double‐blind, and the <a href="./references#CD003748-bbs2-0046" title="Otsuka America. Pletal (Cilostazol) Tablets. Study PUIC-2. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study PUIC‐2</a> abstract did not contain enough information on the methods and results of the study to be included. </p> <p>One study is awaiting classification because we could not source the publication (<a href="./references#CD003748-bbs2-0048" title="SapelkinSV , KharazovAF . Advanced position in the conservative treatment of patients with peripheral arterial disease. Khirurgiia2013;4:68-73. ">Sapelkin 2013</a>). </p> </section> </section> <section id="CD003748-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD003748-fig-0002">Figure 2</a> and <a href="#CD003748-fig-0003">Figure 3</a> offer graphical summaries of risk of bias for the 16 included studies. </p> <div class="figure" id="CD003748-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003748-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003748-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003748-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003748-sec-0045"> <h4 class="title">Allocation</h4> <p>Thirteen studies did not clearly describe randomisation sequence generation methods, leading to a rating of unclear risk of bias. Randomisation sequence generation was low risk in only three studies: two studies reported voice‐interactive computerised methods of randomisation (<a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>), and <a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a> reported the use of a coded randomisation list. Eleven studies provided insufficient information to permit judgement of risk of bias and were rated as being unclear. </p> <p>Five studies were rated as having low risk for allocation concealment: <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> and <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a> used computerised methods to help ensure that the participants and researchers could not determine the treatment allocation; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>, <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> and <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> used coded or sealed envelopes to conceal allocation. The remaining eleven studies provided insufficient information to permit judgement of risk of bias and were rated as being unclear. </p> </section> <section id="CD003748-sec-0046"> <h4 class="title">Blinding</h4> <p>Although all 16 included studies used a placebo control, only half (eight) of the studies adequately described their methods of blinding to ensure that both participants and researchers would not be able to determine treatment and these were rated as being at low risk of bias (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The remaining eight studies were rated as being unclear. </p> <p>None of the studies described blinding of assessors for all outcomes measured, but three studies (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) did give a detailed description of assessor blinding for some of their outcomes, so we determined their risk of detection bias was low. The other 13 studies were rated as having unclear risk of detection bias. </p> </section> <section id="CD003748-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Thirteen studies were at low risk of attrition bias and three studies had unclear risk of attrition bias (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). Study authors in one study (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>) stated analysis would be performed on participants that completed the study (not intention‐to‐treat), but did not specifically state the number of participants that completed the study. The <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> study has two publications; the results tables in one reference included values that would suggest all participants were included in the analysis, and therefore completed the trial. However, the number of participants reported in the other reference had two participants missing, with no explanation. The <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a> study had an overlap of reasons for participants that dropped out, with no discussion of multiple reasons for dropouts. The data and information on the <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a> study were retrieved from a secondary NICE report, and not enough detail was provided to determine incomplete outcome data. </p> </section> <section id="CD003748-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Six studies had a low risk of reporting bias because all indicated outcomes and time points were reported on (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>). Two studies had an unclear risk of reporting bias; in one study, there was inadequate reporting of outcomes (<a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>), and in another study two publications reported on different outcomes with no clear indication of what the preplanned outcomes were (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>). Eight studies had a high risk of reporting bias because they described in the methods outcomes or time points of interest that were not reported on (<a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). </p> </section> <section id="CD003748-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>All 16 studies had a low risk of other potential sources of bias.</p> </section> </section> <section id="CD003748-sec-0050"> <h3 class="title" id="CD003748-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD003748-tbl-0001"><b>Summary of findings 1</b> Cilostazol compared with placebo for intermittent claudication</a>; <a href="./full#CD003748-tbl-0004"><b>Summary of findings 2</b> Cilostazol compared with pentoxifylline for intermittent claudication</a> </p> <p>For the primary outcome of ICD, 14 of the 16 included studies reported this outcome. However, only six of these studies were reported in an adequate and appropriate manner to be included in the meta‐analyses. This was due to methodological differences in the reporting of outcomes that did not allow us to calculate mean change and standard deviations (SD). Also, due to the large differences between studies, we deemed imputation inappropriate. Descriptions of the findings of these studies are addressed under the appropriate outcome headings. <a href="#CD003748-tbl-0005">Table 3</a> describes the reasoning why these studies could not appropriately be included in the meta‐analyses of walking distances and ABI. Data from five studies were gathered solely from unpublished study data (<a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>). </p> <p>We conducted sensitivity analyses by removing studies of a lower methodological quality (defined as studies with five or more high‐risk or unclear‐risk ratings within the seven domains evaluated for risk of bias). We only performed this type of sensitivity analysis for analyses and outcomes where there were sufficient data within the meta‐analyses; this included the comparison of cilostazol versus placebo, and for the outcomes ICD, ACD, adverse events and all‐cause mortality. For the adverse events of abnormal stools and dizziness, and for ABI there were no studies defined as low quality and so these sensitivity analyses were not undertaken. </p> <section id="CD003748-sec-0051"> <h4 class="title">Cilostazol versus placebo</h4> <p><a href="./full#CD003748-tbl-0001">summary of findings Table 1</a> provides a summary of the results for the comparison of cilostazol versus placebo. We carried out subgroup analysis to investigate any overall effect of cilostazol and also to compare the different cilostazol doses. Two studies compared cilostazol 50 mg twice daily with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>), all 16 included studies compared cilostazol 100 mg twice daily with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>; <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) and one study compared cilostazol 150 mg twice daily with placebo (<a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>). </p> <section id="CD003748-sec-0052"> <h5 class="title">Initial claudication distance</h5> <p>Two studies (400 participants) compared cilostazol 50 mg with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) and the fixed‐effect model found a higher ICD (MD 19.50 metres, 95% CI 6.80 to 32.21 metres) in the cilostazol treatment group compared with the placebo group (<a href="./references#CD003748-fig-0004" title="">Analysis 1.1</a>). </p> <p>Six studies (1236 participant) comparing cilostazol 100 mg versus placebo were eligible for inclusion in the meta‐analysis (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). In the fixed‐effect model, participants taking cilostazol had a higher ICD, with a MD of 32.19 metres (95% CI 22.20 to 42.18 metres), compared with those taking placebo (<a href="./references#CD003748-fig-0004" title="">Analysis 1.1</a>). </p> <p>One study (86 participants) compared cilostazol 150 mg versus placebo (<a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>) and the fixed‐effect model found no observable difference between the treatment groups in ICD (MD 15.70 metres, 95% CI ‐12.20 to 43.60 metres). As only one study was included in the analysis, an overall association could not be determined (<a href="./references#CD003748-fig-0004" title="">Analysis 1.1</a>). </p> <p>Overall, six studies (1722 participants) were included in the meta‐analysis that compared cilostazol (all doses) versus placebo. In the fixed‐effect model, participants taking cilostazol had a higher ICD, with a MD of 26.49 metres (95% CI 18.93 to 34.05 metres), compared with those taking placebo (<a href="./references#CD003748-fig-0004" title="">Analysis 1.1</a>). No differences were seen with subgroup analysis (test for subgroup differences: P = 0.22). When low‐quality studies were removed in sensitivity analysis, there was an additional improvement of 3.03 meters in favour of cilostazol (MD 29.52, 95% CI 21.26 to 37.78) and there was a subgroup difference (P = 0.04). </p> <p>Eight additional studies reported data on change in ICD compared with baseline, but the data were not eligible for inclusion in the meta‐analysis (<a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>; <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> reported change in initial claudication time, with participants in the cilostazol group showing an increase of 60 seconds ± standard deviation (SD) of 95 seconds, and the placebo group showing a smaller increase of 44 seconds ± 102 seconds. The report by <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> did not break down the ICD outcome by treatment group, and an estimate of change in ICD is meaningless for the whole study population. <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> reported no difference in the change in effect between the cilostazol group and placebo, 67.0% and 51.6%, respectively, P = 0.63. <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a> reported an arithmetic placebo‐corrected mean change of 41.9 metres and a statistically significant ratio of geometric mean changes of 1.32 (95% CI 1.07 to 1.64; P = 0.01), favouring cilostazol. In contrast, <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a> reported a mean change of ‐2.5 metres for the cilostazol group and 34.4 metres for the placebo group, and a statistically significant ratio of geometric mean changes of 0.69 (95% CI 0.53 to 0.91; P = 0.01), favouring the placebo group. <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a> also reported findings favouring placebo, with an arithmetic placebo‐corrected mean change of ‐92 metres, and a non‐significant ratio of geometric mean changes of 0.69 (95% CI 0.42 to 1.13; P = 0.13). <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a> reported a placebo‐corrected mean change of 15 metres and a ratio of geometric mean changes of 1.01, favouring cilostazol. <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a> reported similar mean changes for the cilostazol and placebo groups of 47.3 metres and 45.3 metres, respectively, and a ratio of geometric mean changes of 1.02 (95% CI 0.92 to 1.13; P = 0.769). </p> <p>Overall, the evidence for this outcome was of low certainty, downgraded one level because of risk of bias (selective reporting) and one level because publication bias was strongly suspected. </p> </section> <section id="CD003748-sec-0053"> <h5 class="title">Health‐related quality of life</h5> <p>Quality of life (QoL) measures were evaluated in four studies (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>) using the self‐administered Short‐Form 36 (SF‐36), Walking Impairment Questionnaire (WIQ), Claudication Outcome Measure (COM), and Vascular Quality of Life (VascuQol) questionnaires. The <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> study reported QoL measures in normoglycaemic patients and diabetic patients, separately. Due to the differences in QoL measures, as well as how they were reported, we did not undertake a meta‐analysis. <a href="./full#CD003748-tbl-0002">Table 1</a> provides information on change in QoL measures as reported in the individual studies. This table should be interpreted with caution, as no hypothesis testing has been performed, and the data format differed between studies. </p> <p>The SF‐36 is a multi‐purpose, general health questionnaire made of 36 questions from eight subscales: physical functioning, role‐physical, bodily pain, general health, vitality, social functioning, role‐emotional and mental health. Each subscale is scored on a scale of zero to 100. The WIQ scale is intended for patients with intermittent claudication and gathers data on walking distance and speed using degree of difficulty scoring from zero to four, with zero representing inability to perform the task and four representing no difficulty. The COM is another disease‐specific testing method for scoring participants with intermittent claudication. It assesses severity of walking pain and discomfort with short and long distances and how participants feel the disease impacts other aspects of their life, including emotional and social. VascuQol is designed for participants with PAD and consists of 25 questions with answer options of one to seven, spanning five domains of interest: physical activity, symptoms, pain, emotion and social aspects. </p> <p>There appeared to be a general improvement in QoL for cilostazol over placebo (various domains, not all domains measured within studies) (SF‐36, <a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>). There were inconsistent results for walking impairment according to the WIQ (four studies), three studies showed no difference between groups for walking impairment (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>) and one study reported a 20% increase in walking speed for the cilostazol group (<a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>). There were modest improvements across the domains of the COM in one study (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>). There was no difference between groups in one study using the VascuQol questionnaire (<a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>). </p> <p>The <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a> study also reported on QoL, with inadequate numerical data to support, but mentioned greater improvement in the cilostazol group compared with placebo, in the physical function, role‐physical and bodily pain scales. <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a> only briefly indicated no difference between the two groups for the endpoint QoL, but the authors did not indicate which questionnaires were used. <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a> reported a statistically significant difference at 12 weeks, favouring cilostazol, compared with placebo, but no data were reported. </p> <p>Overall, the evidence for this outcome was of low certainty, downgraded one level for imprecision because a range of QoL measurement tools were used and results were reported in different ways and one level for strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0054"> <h5 class="title">Absolute claudication distance</h5> <p>Two studies (400 participants) compared cilostazol 50 mg with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>), and the resulting random‐effect meta‐analysis found a higher ACD in the cilostazol arm (MD 30.84 metres, 95% CI 8.81 to 52.86 metres) (<a href="./references#CD003748-fig-0005" title="">Analysis 1.2</a>). </p> <p>Eight studies (1874 participants) were included in the meta‐analysis for ACD comparing cilostazol 100 mg versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The results of the random‐effects model showed a higher ACD in the cilostazol arm (MD 42.32 metres, 95% CI 18.12 to 66.51 metres) (<a href="./references#CD003748-fig-0005" title="">Analysis 1.2</a>). </p> <p>One study of 86 participants (<a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>), compared cilostazol 150 mg with placebo, and found a MD of 51.80 metres with a wide 95% CI spanning ‐10.59 to 114.19 (<a href="./references#CD003748-fig-0005" title="">Analysis 1.2</a>). </p> <p>Overall, eight studies (2360 participants) were included in the meta‐analysis that compared cilostazol (all doses) versus placebo. Heterogeneity was detected so we used the random‐effects model. Participants taking cilostazol had a higher ACD, with a MD of 39.57 metres (95% CI 21.80 to 57.33 metres), compared with those taking placebo (<a href="./references#CD003748-fig-0005" title="">Analysis 1.2</a>). No differences were seen with subgroup analysis (test for subgroup differences: P = 0.70). When low‐quality studies were removed in sensitivity analysis, there was there was an additional improvement of 8.87 meters in favour of cilostazol (MD 48.44, 95% CI 34.49 to 62.39). </p> <p>Eight additional studies reported on ACD, but their data were incompatible for meta‐analysis (<a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>; <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>; <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>; <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>). <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> measured peak walking time, similar to ACD, and found that the mean change (± SD) from baseline for the cilostazol group was 122 seconds ± 190 seconds, and for the placebo group a mean change of 72 seconds ± 196 seconds. The <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> study reported a mean change in maximal walking distance, 'expressed as per cent of control' of approximately 130% to 140%. These data were read from a graph, and no further information was given on the placebo arm. <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> reported a statistically significant increased change in effect between the cilostazol group and placebo, 161.7% and 79.0%, respectively, P = 0.048. <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a> reported a placebo‐corrected arithmetic mean change for the cilostazol group of 49.7 metres, and a non‐significant ratio of geometric means of 1.17 (95% CI 0.97 to 1.42; P = 0.09). <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>'s results did not support cilostazol for increased ACD, with a mean change of ‐6.9 metres for the cilostazol group and 30.3 metres for the placebo group, and a statistically significant ratio of geometric means of 0.83 (95% CI 0.70 to 0.98; P = 0.03), favouring the placebo arm. <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a> also reported ACD results that did not support cilostazol with a placebo‐corrected mean change for the cilostazol group of ‐99.1 metres, and a ratio of geometric means of 0.83 (95% CI 0.46 to 1.51; P = 0.52). <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a> reported a placebo‐corrected arithmetic mean change for the cilostazol group of 33.6 metres and a ratio of geometric means of 1.06, favouring cilostazol. <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> reported a baseline ACD for the cilostazol group of 111 metres (SD 30) and follow‐up of 145 (SD 53). The placebo group had a baseline ACD of 116 metres (SD 56) and follow‐up of 121 (SD 62), with no difference between the time points. </p> <p>Overall, the evidence for this outcome was of very low certainty, downgraded one level for risk of bias (selective reporting), one level for inconsistency (heterogeneity) and one level for strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0055"> <h5 class="title">Revascularisation (angioplasty or surgical bypass)</h5> <p>One study (516 participants) compared both cilostazol 50 mg twice daily and cilostazol 100 mg twice daily versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>) and found no clear difference in the odds of arterial revascularisation with OR 0.16 (95% CI 0.01 to 4.07, <a href="./references#CD003748-fig-0006" title="">Analysis 1.3</a>). The evidence for this outcome was of very low certainty, downgraded by two levels for imprecision and one level for strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0056"> <h5 class="title">Amputation</h5> <p>One study (516 participants) compared both cilostazol 50 mg twice daily and cilostazol 100 mg twice daily versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>), and found no clear difference in the odds of amputation with OR 0.16 (95% CI 0.01 to 4.07, <a href="./references#CD003748-fig-0007" title="">Analysis 1.4</a>). The evidence for this outcome was of very low certainty, downgraded by two levels for imprecision and one level for strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0057"> <h5 class="title">Adverse events related to study medication</h5> <p>Eight of the included studies recorded data on side effects in a format eligible for meta‐analysis (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The side effects reported varied between the studies, but the most common events were headache, diarrhoea, abnormal stools, dizziness, pain and palpitations, which are discussed below. </p> <p>The <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> study reported several side effects in a combined events outcome, which was not appropriate to include in the meta‐analyses. Combined adverse events were reported in <a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a>, <a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a>, <a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a>, <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a> and <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>, but only for participants who dropped out of the study. These events were not considered in the meta‐analyses. <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> reported no significant subjective side effects in the cilostazol or placebo group, but did not define what they considered a side effect. </p> <section id="CD003748-sec-0058"> <h6 class="title">Headache</h6> <p>Two studies (453 participants) reported on headache when comparing cilostazol 50 mg twice daily versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). Meta‐analysis using a fixed‐effect model, showed an increased odds of headache in the cilostazol 50 mg twice daily group with OR 2.02 (95% CI 1.19 to 3.43) versus the placebo group (<a href="./references#CD003748-fig-0008" title="">Analysis 1.5</a>). </p> <p>Eight studies (2131 participants) reported on headache when comparing cilostazol 100 mg twice daily versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). Meta‐analysis using a fixed‐effect model, showed an increased odds of headache in the cilostazol 100 mg twice daily group with OR 3.05 (95% CI 2.38 to 3.92) versus the placebo group (<a href="./references#CD003748-fig-0008" title="">Analysis 1.5</a>). </p> <p>Overall, eight studies (2584 participants) reported on headache when comparing cilostazol (all doses) versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). Meta‐analysis using a fixed‐effect model, showed an increased odds of headache in the cilostazol group with OR 2.83 (95% CI 2.26 to 3.55) versus the placebo group (<a href="./references#CD003748-fig-0008" title="">Analysis 1.5</a>). Incidence rates were 380/1456 for cilostazol participants and 119/1128 for placebo participants. No differences were seen with subgroup analysis (test for subgroup differences: P = 0.17). When low‐quality studies were removed in sensitivity analysis, there was very little change in the odds of headache in the cilostazol group versus placebo, OR 2.83, (95% CI 2.21 to 3.61, <a href="./references#CD003748-fig-0019" title="">Analysis 1.16</a>). </p> <p>Overall, the evidence for this outcome was of moderate certainty, downgraded one level for strongly suspected publication bias. <a href="./full#CD003748-tbl-0003">Table 2</a> grades the evidence for other adverse events related to study medication. </p> </section> <section id="CD003748-sec-0059"> <h6 class="title">Diarrhoea</h6> <p>Two studies (453 participants) compared cilostazol 50 mg with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The fixed‐effect model found no clear difference between groups, OR 2.02 (95% CI 0.91 to 4.52) for the 50 mg comparison (<a href="./references#CD003748-fig-0009" title="">Analysis 1.6</a>). </p> <p>Seven studies (2050 participants) compared cilostazol 100 mg twice daily with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The fixed‐effect model found an increased odds in the cilostazol group: OR 2.88 (95% CI 2.07 to 3.99, <a href="./references#CD003748-fig-0009" title="">Analysis 1.6</a>). </p> <p>Overall, seven studies (2503 participants) compared cilostazol (all doses) with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The fixed‐effect model found an increased odds in the cilostazol group: OR 2.73 (95% CI 2.02 to 3.70, <a href="./references#CD003748-fig-0009" title="">Analysis 1.6</a>). Incidence rates were 190/1402 for cilostazol participants and 62/1101 for placebo participants. No differences were seen with subgroup analysis (test for subgroup differences: P = 0.43). When low‐quality studies were removed in sensitivity analysis, there was very little change in the meta‐analyses results, OR 2.91, (95% CI 2.05 to 4.12, <a href="./references#CD003748-fig-0020" title="">Analysis 1.17</a>). </p> <p><a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a> collected data on gastrointestinal complaints compilation, which included diarrhoea and abnormal stools, but the data was not broken down into individual adverse events and could not be used in meta‐analysis. </p> </section> <section id="CD003748-sec-0060"> <h6 class="title">Abnormal stools</h6> <p>Two studies (453 participants) compared cilostazol 50 mg versus placebo and found no difference between the treatment groups, OR 2.48 (95% CI 1.08 to 5.71) using a fixed‐effect model (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) (<a href="./references#CD003748-fig-0010" title="">Analysis 1.7</a>). </p> <p>Five studies (1351 participants) compared cilostazol 100 mg with placebo and found an increased odds of abnormal stools in the cilostazol group, OR 4.04 (95% CI 2.59 to 6.31), using a fixed‐effect model (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) (<a href="./references#CD003748-fig-0010" title="">Analysis 1.7</a>). </p> <p>Overall, five studies (1804 participants) compared cilostazol (all doses) with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The fixed‐effect model found an increased odds in the cilostazol group: OR 3.63 (95% CI 2.45 to 5.38, <a href="./references#CD003748-fig-0010" title="">Analysis 1.7</a>). Incidence rates of abnormal stools were 150/1052 for cilostazol participants and 33/752 for placebo participants. No differences were seen with subgroup analysis (test for subgroup differences: P = 0.31)<b>.</b> </p> </section> <section id="CD003748-sec-0061"> <h6 class="title">Dizziness</h6> <p>A single study compared cilostazol 50 mg with placebo and found no clear difference between the two treatment groups, OR 1.95 (95% CI 0.63 to 6.06) (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>) (<a href="./references#CD003748-fig-0011" title="">Analysis 1.8</a>). </p> <p>For the comparison between cilostazol 100 mg and placebo, four studies (864 participants) recorded data on dizziness (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>). The results of the fixed‐effect meta‐analysis found an increased odds of dizziness in the cilostazol group, OR 2.57 (95% CI 1.42 to 4.63, <a href="./references#CD003748-fig-0011" title="">Analysis 1.8</a>). </p> <p>Overall, four studies (1120 participants) compared cilostazol (all doses) versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>). The results of the fixed‐effect meta‐analysis found an increased odds of dizziness in the cilostazol group, OR 2.42 (95% CI 1.43 to 4.08, <a href="./references#CD003748-fig-0011" title="">Analysis 1.8</a>). Incidence rates were 63/649 for cilostazol participants and 20/471 for placebo participants. No differences were seen with subgroup analysis (test for subgroup differences: P = 0.67). </p> </section> <section id="CD003748-sec-0062"> <h6 class="title">Pain</h6> <p>Pain was reported in one study (197 participants) comparing cilostazol 50 mg versus placebo (<a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>); it found no clear difference between treatment groups, OR 1.53 (95% CI 0.67 to 3.48) (<a href="./references#CD003748-fig-0012" title="">Analysis 1.9</a>). </p> <p>Pain was reported in four studies (1375 participants) comparing cilostazol 100 mg versus placebo (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). There was no clear difference in the fixed‐effect model for cilostazol 100 mg versus placebo: OR 0.88 (95% CI 0.64 to 1.23, <a href="./references#CD003748-fig-0012" title="">Analysis 1.9</a>). </p> <p>Overall, four studies (1572 participants) compared cilostazol (all doses) with placebo (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). There was no clear difference in the fixed‐effect model for cilostazol versus placebo: OR 0.96 (95% CI 0.71 to 1.30, <a href="./references#CD003748-fig-0012" title="">Analysis 1.9</a>). Incidence rates were 107/848 for cilostazol participants and 92/724 for placebo participants. No differences were seen with subgroup analysis (test for subgroup differences: P = 0.23). When low‐quality studies were removed in sensitivity analysis, there was very little change in the meta‐analyses results, OR 1.07, (95% CI 0.75 to 1.54, <a href="./references#CD003748-fig-0021" title="">Analysis 1.18</a>). </p> </section> <section id="CD003748-sec-0063"> <h6 class="title">Palpitations</h6> <p>The occurrence of palpitations was measured in one study (256 participants) comparing cilostazol 50 mg versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>); it found a higher odds in the cilostazol group, with a very wide CI, OR 8.89 (95% CI 0.51 to 155.87), but with only a single study, an overall association could not be determined (<a href="./references#CD003748-fig-0013" title="">Analysis 1.10</a>). </p> <p>The occurrence of palpitations was measured in four studies (1425 participants) comparing cilostazol 100 mg versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). The fixed‐effects model found an increased odds of palpitations in the cilostazol group, OR 7.06 (95% CI 3.85 to 12.96, <a href="./references#CD003748-fig-0013" title="">Analysis 1.10</a>).   </p> <p>Overall, four studies (1681 participants) compared cilostazol (all doses) with placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). The fixed‐effects model found an increased odds of palpitations in the cilostazol group, OR 7.16 (95% CI 3.95 to 12.98, <a href="./references#CD003748-fig-0013" title="">Analysis 1.10</a>). Incidence rates were 94/923 for cilostazol participants and 12/758 for placebo participants. No differences were seen with subgroup analysis (test for subgroup differences: P = 0.88). When low‐quality studies were removed in sensitivity analysis, there was an increased odds in the cilostazol group versus placebo (OR 12.80, 95% CI 5.06 to 32.36, <a href="./references#CD003748-fig-0022" title="">Analysis 1.19</a>). </p> </section> </section> <section id="CD003748-sec-0064"> <h5 class="title">Cardiovascular events</h5> <p>Two studies (692 participants) reported cardiovascular events (myocardial infarction and stroke) that compared cilostazol (all doses) versus placebo (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>). Meta‐analysis using a fixed‐effect model, showed no clear difference in the odds of cardiovascular events with OR 1.50 (95% CI 0.51 to 4.47) versus the placebo group (<a href="./references#CD003748-fig-0014" title="">Analysis 1.11</a>). No differences were seen with subgroup analysis by cilostazol dose (test for subgroup differences: P = 1.0). <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> reported serious adverse cardiac events, but did not report a breakdown of the types of events included. The cilostazol group experienced one cardiac event and the placebo group had three, but they were not statistically different; P = 0.365. Overall, the evidence for this outcome was of low certainty, downgraded one level for imprecision and one level for strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0065"> <h5 class="title">All‐cause mortality</h5> <p>All‐cause mortality was reported in eight studies (2642 participants) (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>). The results of the fixed‐effect model found no clear difference between the treatment groups, with an OR of 0.97 (95% CI 0.41 to 2.30, <a href="./references#CD003748-fig-0015" title="">Analysis 1.12</a>). No differences were seen with subgroup analysis by cilostazol dose (test for subgroup differences: P = 0.62). When low‐quality studies were removed, there was little change in the meta‐analyses results (OR 1.21, 95% CI 0.47 to 3.13). </p> </section> <section id="CD003748-sec-0066"> <h5 class="title">Ankle brachial index</h5> <p>Three studies were included in the meta‐analysis for ABI (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>); the results from the random‐effects model was a higher ABI in the cilostazol arm of 0.06 (95% CI 0.04 to 0.08, <a href="./references#CD003748-fig-0016" title="">Analysis 1.13</a>). </p> <p>In addition, two studies reported ABI that could not be included in the meta‐analysis (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>). The <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> study reported on ABI, but because they only reported interquartile range for the baseline and follow‐up measurements, and they only reported ABI in a subgroup of normoglycaemic participants, the data were not comparable. The cilostazol group had a median change of ABI of ‐0.05 on the right side of the body and median change of ‐0.04 on the left side of the body. In comparison, the placebo group had a median ABI change of ‐0.03 on the right side of the body and ‐0.08 on the left. <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> reported no differences from baseline to follow‐up for any of the treatment groups. The cilostazol treatment group had a baseline measure of 0.73 (SD 0.12) and follow‐up of 0.69 (SD 0.11), while the placebo group had a baseline of 0.69 (SD 0.12) and follow‐up of 0.71 (SD 0.13). </p> </section> <section id="CD003748-sec-0067"> <h5 class="title">Major Adverse Limb Event</h5> <p>None of the studies reported this outcome.</p> </section> </section> <section id="CD003748-sec-0068"> <h4 class="title">Cilostazol versus pentoxifylline</h4> <p><a href="./full#CD003748-tbl-0004">summary of findings Table 2</a> provides a summary of the results for the comparison of cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily. Five studies were included for this comparison (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). </p> <section id="CD003748-sec-0069"> <h5 class="title">Initial claudication distance</h5> <p>A single study compared cilostazol 100 mg with pentoxifylline 400 mg (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>), and the fixed‐effect model found no observable difference between the treatment groups in ICD (MD 20.00 metres, 95% CI ‐2.57 to 42.57 metres). As only one study was included in the analysis, an overall association could not be determined (<a href="./references#CD003748-fig-0024" title="">Analysis 2.1</a>). </p> <p>Additionally, three studies that could not be included in the meta‐analysis compared change in ICD from baseline between cilostazol 100 mg and pentoxifylline 400 mg (<a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). The report by <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> did not break down the ICD outcome by treatment group, and reported only an estimate of change in ICD for the whole study population split according to smoking status. <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a> reported a placebo‐corrected mean change of 10 metres in the pentoxifylline group and a ratio of geometric mean change from baseline of 1.02, favouring pentoxifylline. The <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a> found an arithmetic mean change of 47.3 metres for the cilostazol group and 62.6 metres for the placebo group suggesting a greater increase for the pentoxifylline group. There was also a non‐significant ratio of geometric means comparing cilostazol with pentoxifylline of 0.94 (95% CI 0.95 to 1.12; P = 0.260). </p> <p>Overall, the evidence for this outcome was of low certainty because of imprecision and strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0070"> <h5 class="title">Health‐related quality of life</h5> <p>One study reported this outcome (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>). The study authors reported that none of the treatments significantly affected the scores on mental health concepts, general health perception, physical health concepts, or vitality scores (SF‐36). There were no significant differences in patient‐reported walking distance or speed (WIQ). Overall, the evidence for this outcome was of very low certainty because of very serious imprecision and strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0071"> <h5 class="title">Absolute claudication distance</h5> <p>Two studies comparing cilostazol 100 mg with pentoxifylline 400 mg could be included in the ACD meta‐analysis (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). The resulting random‐effects model found no difference between the treatment groups with a MD of 13.41 metres (95% CI ‐43.50 to 70.36 metres, <a href="./references#CD003748-fig-0025" title="">Analysis 2.2</a>). </p> <p>Additionally, three studies that could not be included in the meta‐analysis compared change in ICD from baseline between cilostazol 100 mg and pentoxifylline 400 mg (<a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>; <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>). The <a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> study did not directly compare cilostazol with pentoxifylline, but reported a mean change in maximal walking distance via a graph, 'expressed as per cent of control' of approximately 50%. <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a> found similar placebo‐corrected mean changes of 33.6 metres for the cilostazol group and 34 metres for the pentoxifylline group, with a treatment effect ratio of cilostazol to pentoxifylline of 0.99, favouring pentoxifylline. <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> reported a baseline ACD for the cilostazol group of 111 metres (SD 30) and follow‐up of 145 (SD 53). The pentoxifylline group had a baseline ACD of 114 (SD 51) and follow‐up of 147 (81). However, the authors of the study did not directly compare the change in ACD between the two treatment groups. </p> <p>Overall, the evidence for this outcome was of very low certainty because of inconsistency, imprecision and strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0072"> <h5 class="title">Revascularisation (angioplasty or surgical bypass)</h5> <p>No study reported this outcome.</p> </section> <section id="CD003748-sec-0073"> <h5 class="title">Amputation</h5> <p>No study reported this outcome.</p> </section> <section id="CD003748-sec-0074"> <h5 class="title">Adverse events related to study medication</h5> <section id="CD003748-sec-0075"> <h6 class="title">Headache</h6> <p>The <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a> and <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a> studies compared cilostazol 100 mg twice daily with pentoxifylline 400 mg three times daily, and the random‐effects model found an increased odds of headache in the cilostazol group, OR 2.20 (95% CI 1.16 to 4.17, <a href="./references#CD003748-fig-0026" title="">Analysis 2.3</a>). Incidence rates were 106/488 for cilostazol participants and 55/494 for placebo participants. </p> <p>Overall, the evidence for this outcome was of low certainty because of heterogeneity and strongly suspected publication bias. </p> </section> <section id="CD003748-sec-0076"> <h6 class="title">Diarrhoea</h6> <p>The two studies comparing cilostazol 100 mg with pentoxifylline 400 mg found, with a random‐effects model, no difference in the odds of diarrhoea between the treatment groups, OR 1.80 (95% CI 0.79 to 4.12) (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>) (<a href="./references#CD003748-fig-0027" title="">Analysis 2.4</a>). Incidence rates were 78/488 for cilostazol participants and 48/494 for placebo participants. </p> </section> <section id="CD003748-sec-0077"> <h6 class="title">Abnormal stools</h6> <p>Only one study (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>) reported abnormal stools for the comparison between cilostazol and pentoxifylline; it found an increased odds of abnormal stools in the cilostazol group, OR 3.12 (95% CI 1.57 to 6.21) (<a href="./references#CD003748-fig-0028" title="">Analysis 2.5</a>). Incidence rates were 33/227 for cilostazol participants and 12/232 for placebo participants. </p> </section> <section id="CD003748-sec-0078"> <h6 class="title">Pain</h6> <p>Pain was reported in two studies comparing cilostazol with pentoxifylline (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). There was no difference in the fixed‐effect model results for cilostazol versus pentoxifylline, OR 0.85 (95% CI 0.57 to 1.26) (<a href="./references#CD003748-fig-0029" title="">Analysis 2.6</a>). Incidence rates were 52/488 for cilostazol participants and 61/494 for placebo participants. </p> </section> <section id="CD003748-sec-0079"> <h6 class="title">Palpitations</h6> <p>The occurrence of palpitations was measured in two studies comparing cilostazol with pentoxifylline (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>); there was an increase in palpitations in the cilostazol group, with a fixed‐effect model, OR 8.35 (95% CI 4.11 to 16.98) (<a href="./references#CD003748-fig-0030" title="">Analysis 2.7</a>). Incidence rates were 65/488 for cilostazol participants and 9/494 for placebo participants. </p> </section> <section id="CD003748-sec-0080"> <h6 class="title">Subjective side effects</h6> <p>Additionally, one study that could not be included in the meta‐analysis (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>), reported no significant subjective side effects in the cilostazol or pentoxifylline group, but did not define what they considered a side effect. </p> </section> </section> <section id="CD003748-sec-0081"> <h5 class="title">Cardiovascular events</h5> <p>No study reported this outcome.</p> </section> <section id="CD003748-sec-0082"> <h5 class="title">All‐cause mortality</h5> <p>Three studies reported on all‐cause mortality comparing cilostazol with pentoxifylline (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>). The fixed‐effect model results found no association between the treatment groups (OR 0.58, 95% CI 0.17 to 1.98) (<a href="./references#CD003748-fig-0031" title="">Analysis 2.8</a>). </p> </section> <section id="CD003748-sec-0083"> <h5 class="title">Ankle brachial index</h5> <p>One study was included in the ABI meta‐analysis for the comparison of cilostazol 100 mg to pentoxifylline 400 mg (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>); it found an ABI MD of ‐0.01 (95% CI ‐0.12 to 0.10), but no overall association could be determined (<a href="./references#CD003748-fig-0032" title="">Analysis 2.9</a>). </p> <p>Additionally, one study that could not be included in the meta‐analysis (<a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>), reported no differences from baseline to follow‐up for any of the treatment groups. The cilostazol treatment group had a baseline measure of 0.73 (SD 0.12) and follow‐up of 0.69 (SD 0.11), while the pentoxifylline group had a baseline of 0.66 (SD 0.13) and follow‐up of 0.70 (SD 0.14). </p> </section> <section id="CD003748-sec-0084"> <h5 class="title">Major Adverse Limb Event</h5> <p>No study reported this outcome.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003748-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003748-sec-0085"></div> <section id="CD003748-sec-0086"> <h3 class="title" id="CD003748-sec-0086">Summary of main results</h3> <section id="CD003748-sec-0087"> <h4 class="title">Cilostazol versus placebo</h4> <p>There is very low to low‐certainty evidence that cilostazol improves walking distance, both in terms of ICD and ACD, compared to placebo. Six studies reported ICD, with a study duration ranging from 12 to 24 weeks, and cilostazol dose ranging from 100 mg to 300 mg. Participants taking cilostazol had a higher ICD, with a MD of 26.49 metres (95% CI 18.93 to 34.05; 1722 participants; 6 studies), compared with those taking placebo. When lower quality studies were removed, there was an additional improvement of three metres in favour of cilostazol (MD 29.52, 95% CI 21.26 to 37.78; 1543 participants; 5 studies) and subgroup differences according to dose (P = 0.04). Participants taking 50 mg cilostazol twice daily had a MD of 19.50 metres (95% CI 6.80 to 32.21; 400 participants; 2 studies) and participants taking 100 mg cilostazol twice daily had a MD of 32.19 metres (95% CI 22.20 to 42.18; 1236 participants; 6 studies). Participants taking cilostazol had a higher ACD, with a MD of 39.57 metres (95% CI 21.80 to 57.33; 2360 participants; 8 studies) compared with those taking placebo. When lower quality studies were removed, there was an additional improvement of nine metres in favour of cilostazol (MD 48.44, 95% CI 34.49 to 62.39; 1732 participants; 6 studies). </p> <p>The value of these increases in walking distance (26 metres further before the onset of calf pain and 40 metres further in terms of total distance) are subjective and depend on the individual patient; some patients may find not much benefit from this additional walking distance but some may find the additional extra walking distance enables them to undertake more daily activities. </p> <p>Four studies reported on quality of life (QoL) but, due to the differences in QoL measures as well as how they were reported, we did not undertake a meta‐analysis. Overall, cilostazol was associated with improvements in some domains of QoL compared to placebo. Very few studies reported on other outcomes making it impossible to draw any conclusions regarding the effectiveness of cilostazol versus placebo on arterial revascularisation, amputation, or cardiovascular events. </p> <p>There was moderate‐certainty evidence that participants taking cilostazol had an increased odds of experiencing headache compared to participants taking placebo, during 12 to 26 weeks intervention (OR 2.83, 95% CI 2.26 to 3.55; 2584 participants; 8 studies); and an increased odds of other commonly reported adverse events including diarrhoea, abnormal stools, dizziness and palpitations. </p> <p>Eight studies reported very few deaths with no difference in all‐cause mortality between cilostazol and placebo groups. Cilostazol (100 mg twice daily) improved ABI over placebo (MD 0.06, 95% CI 0.04 to 0.08; 859 participants; 3 studies). </p> <p>The certainty of the evidence was downgraded by one level for all studies because publication bias was strongly suspected. Other issues that necessitated downgrading included risk of selective reporting, imprecision and inconsistency. </p> </section> <section id="CD003748-sec-0088"> <h4 class="title">Cilostazol versus pentoxifylline</h4> <p>There is very low to low‐certainty evidence of no difference between cilostazol and pentoxifylline for improving walking distance, both in terms of ICD (MD 20.00, 95% CI ‐2.57 to 42.57; 417 participants; 1 study) and ACD (MD 13.43, 95% CI ‐43.50 to 70.36; 866 participants; 2 studies). </p> <p>One study reported on QoL; the study authors reported no difference in QoL between the treatment groups. No study reported on revascularisation, amputation or cardiovascular events. There was low‐certainty evidence that cilostazol participants had an increased odds of experiencing headache compared to participants taking pentoxifylline at 24 weeks (OR 2.20, 95% CI 1.16 to 4.17; 982 participants; 2 studies); and an increased odds of experiencing abnormal stools, and palpitations, but there was no difference between treatment groups for diarrhoea or pain. There was no clear difference between treatment groups for all‐cause mortality or ABI. </p> <p>Certainty of the evidence was downgraded by one level for all studies because publication bias was strongly suspected. Other issues that necessitated downgrading included imprecision and inconsistency. </p> </section> </section> <section id="CD003748-sec-0089"> <h3 class="title" id="CD003748-sec-0089">Overall completeness and applicability of evidence</h3> <p>This review addressed whether the use of cilostazol reduced symptoms of intermittent claudication (specifically ICD and ACD) in participants with stable intermittent claudication. All 16 included studies evaluated the effects of cilostazol compared with placebo, within similar study populations. Most of the included evidence is for the comparison of cilostazol versus placebo, the two walking distance outcomes (ICD and ACD) and for the cilostazol dose of 100 mg twice daily. We identified very limited data on QoL, other serious outcomes of amputation, revascularisation and cardiovascular events, and all‐cause mortality, both in terms of the number of studies reporting these outcomes and few events reported within those studies. </p> <p>Treatment duration ranged from six to 26 weeks, with the most common treatment time at 24 weeks. Most of the included studies only reported change from baseline for the final time point, so we were unable to compare studies at a common time point. Treadmill protocols ranged between three main protocols. The aberrations between the testing protocols were addressed by using change in mean walking distances, rather than absolute follow‐up distance, which does not account for baseline measures. These differences and limitations alter the strength of the applicability of the evidence, and should be kept in mind when interpreting the findings. Only two of the included studies defined their baseline treadmill test values when multiple baseline values were obtained (<a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>). Both studies used the highest baseline treadmill value for analysis, while the remaining studies did not indicate their methods. Possible variations in treadmill testing baseline definition could reduce the applicability of the findings. </p> <p>Many included studies were quite 'old' and were carried out before best medical treatment was recommended or applied in patients with stable intermittent claudication and so a further limitation to this evidence is that it might not be an accurate representation of current practice. Also, dose recommendation for pentoxifylline is either 400 mg three times daily or 400 mg twice daily; one included study did not reflect current dosing practice as it used a pentoxifylline dose of 600 mg twice daily (<a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a>). We only identified studies comparing cilostazol versus placebo, and cilostazol versus pentoxifylline; studies comparing cilostazol with other agents, such as naftidrofuryl, were not identified. </p> </section> <section id="CD003748-sec-0090"> <h3 class="title" id="CD003748-sec-0090">Quality of the evidence</h3> <p>We included 16 studies with 3972 participants. Using GRADE assessment, all studies (both comparisons) were downgraded one level because publication bias was strongly suspected, with pharmaceutical sponsors involved in all 16 studies (of which 13 involved the same pharmaceutical company (Otsuka)). </p> <p>Using GRADE assessment, the body of evidence relating to cilostazol compared with placebo was judged to be of very low (ACD, revascularisation, amputation), low (ICD, QoL, cardiovascular outcomes) to moderate (adverse events ‐ headache) certainty. Other issues that necessitated downgrading included risk of selective reporting, imprecision and inconsistency. </p> <p>Using GRADE assessment, the body of evidence relating to cilostazol compared with pentoxifylline was judged to be of very low (QoL, ACD), to low (ICD, adverse events ‐ headache) certainty. Other issues that necessitated downgrading included imprecision and inconsistency. </p> <p>Certainty of the evidence was based on those studies in the summary of findings tables and (with the exception of QoL) this evidence comes from the meta‐analyses. The risk of bias assessments of those studies not included in the meta‐analyses was consistent with risk of bias assessments of studies included in the meta‐analyses. However, it should be noted that data in a significant proportion of studies was poorly reported, and we were unable to incorporate such data in any of the meta‐analyses. </p> <p>Six studies were never published as journal articles, with sources of data being a medical review by the FDA in five cases and a pharmaceutical submission to NICE in another case. Seven studies were published journal articles, however, the data used for six of these studies were derived from pharmaceutical data submitted to the FDA rather than the associated publications. </p> </section> <section id="CD003748-sec-0091"> <h3 class="title" id="CD003748-sec-0091">Potential biases in the review process</h3> <p>Study selection and data extraction were performed independently by two review authors in order to minimise bias in the review process. The inclusion and exclusion criteria of the review were strictly adhered to in order to limit subjectivity. </p> <p>For the primary outcome of ICD, 14 of the 16 included studies reported this outcome. However, only six of these studies were reported in an adequate and appropriate manner to be included in the meta‐analyses. Following consultation with a statistician, other forms of imputation were not carried out due to methodological differences in the reporting of outcomes that did not allow us to calculate mean change and standard deviations. Also, due to the large differences between studies, we deemed imputation inappropriate. For the <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a> study, standard deviations were provided for the ABI outcome for mean change in the comparison between cilostazol and placebo, but not for cilostazol compared to pentoxifylline. We calculated correlation coefficients using the existing mean change standard deviations and imputed values to calculate mean change standard deviations for the comparison between cilostazol and pentoxifylline. </p> </section> <section id="CD003748-sec-0092"> <h3 class="title" id="CD003748-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>The evidence presented here is consistent with the findings of two older reviews (<a href="./references#CD003748-bbs2-0074" title="RegensteinerJG , Ware JE Jr, McCarthyWJ , ZhangP , ForbesWP , HeckmanJ , et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. Journal of the American Geriatrics Society2002;50(12):1939-46.">Regensteiner 2002</a>; <a href="./references#CD003748-bbs2-0083" title="ThompsonPD , ZimetR , ForbesWP , ZhangP . Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. American Journal of Cardiology2002;90(12):1314-9.">Thompson 2002</a>) which evaluated the effects of cilostazol for intermittent claudication and found similar improvements in walking distances for participants taking cilostazol. A systematic review published in 2012 comparing cilostazol, naftidrofuryl oxalate and pentoxifylline with placebo for the treatment of intermittent claudication in patients with PAD included six of the same studies as our review (<a href="./references#CD003748-bbs2-0082" title="StevensJW , SimpsonE , HarnanS , SquiresH , MengY , ThomasS , et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery2012;99(12):1630-8.">Stevens 2012</a>). For inclusion in meta‐analysis, the study authors employed imputation techniques that we ourselves did not use and they reported their findings for ICD (reported as maximum walking distance) and ACD (reported as pain‐free walking distance) as geometric mean changes compared with placebo. However, their results also found increases in both ICD and ACD for the cilostazol groups, compared with placebo, with an increase in ICD of 25% (95% credible interval 11% to 40%) and an ACD increase of 13% (95% credible interval 2% to 26%). Adverse events were not reported in the meta‐analysis, but headaches and gastrointestinal issues that were mild were noted in the intervention arms and there was no increase in cardiovascular events or deaths for cilostazol, naftidrofuryl oxalate or pentoxifylline. The authors noted that the heterogeneity of QoL reporting did not allow them to report those findings in their review. </p> <p>The data from Stevens and colleagues (<a href="./references#CD003748-bbs2-0082" title="StevensJW , SimpsonE , HarnanS , SquiresH , MengY , ThomasS , et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery2012;99(12):1630-8.">Stevens 2012</a>) is also presented as part of <a href="./references#CD003748-bbs2-0080" title="SquiresH , SimpsonE , MengY , HarnanS , StevensJ , WongR , National Institute for Health and Clinical Excellence. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication in people with peripheral arterial disease. Technology Assessment Report commissioned by the NIHR HTA Programme. www.guidance.nice.org.uk/nicemedia/live/12265/51580/51580.pdf (accessed May 2014).">Squires 2010</a> and <a href="./references#CD003748-bbs2-0081" title="SquiresH , SimpsonE , MengY , HarnanS , StevensJ , WongR , et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technology Assessment2011;15(40):1-210. [DOI: 10.3310/hta15400]">Squires 2011</a> as technology assessment reports written for the National Institute for Health and Care Excellence (<a href="./references#CD003748-bbs2-0070" title="National Institute for Health and Care Excellence (NICE). Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. nice.org.uk/guidance/TA223/chapter/2-Clinical-need-and-practice (accessed 11 July 2014).">NICE 2011</a>). These assessment reports continue to underpin the current NICE guideline (CG147) and there has been no major change to this guideline in relation to treatment of intermittent claudication, since its publication in 2012 and last updated in December 2020 (<a href="./references#CD003748-bbs2-0071" title="National Institute for Health and Care Excellence (NICE). Peripheral arterial disease: diagnosis and management (last updated December 2020). nice.org.uk/Guidance/CG147 (accessed 12 March 2021).">NICE 2012</a>). Our review confirms that there is very little new RCT evidence for cilostazol for people with intermittent claudication. We did not identify any newer systematic reviews of cilostazol for intermittent claudication. </p> <p>Two of the studies in our review that compared cilostazol versus pentoxifylline (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a>) were included in another Cochrane review of pentoxifylline (<a href="./references#CD003748-bbs2-0052" title="BroderickC , ForsterR , Abdel-HadiM , SalhiyyahK . Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262.pub4]">Broderick 2020</a>) where review authors concluded that the data from studies comparing cilostazol with pentoxifylline 'were too limited to allow meaningful conclusions'. In patients in whom symptoms do not improve with exercise and risk factor management, medical management using pharmacological interventions, such as cilostazol (<a href="./references#CD003748-bbs2-0049" title="AboyansV , RiccoJB , BartelinkME , BjörckM , BrodmannM , CohnertT , et al, ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal2018;39(9):763-816.">Aboyans 2018</a>; <a href="./references#CD003748-bbs2-0058" title="Gerhard-HermanMD , GornikHL , BarrettC , BarshesNR , CorriereMA , DrachmanDE , et al. 2016 AHA/ACC Guidelines on the Management of Patients with Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology2017;69:e71-e126.">Gerhard‐Herman 2017</a>; <a href="./references#CD003748-bbs2-0049" title="AboyansV , RiccoJB , BartelinkME , BjörckM , BrodmannM , CohnertT , et al, ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal2018;39(9):763-816.">Aboyans 2018</a>), naftidrofuryl (<a href="./references#CD003748-bbs2-0049" title="AboyansV , RiccoJB , BartelinkME , BjörckM , BrodmannM , CohnertT , et al, ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal2018;39(9):763-816.">Aboyans 2018</a>; <a href="./references#CD003748-bbs2-0071" title="National Institute for Health and Care Excellence (NICE). Peripheral arterial disease: diagnosis and management (last updated December 2020). nice.org.uk/Guidance/CG147 (accessed 12 March 2021).">NICE 2012</a>) and pentoxifylline (<a href="./references#CD003748-bbs2-0049" title="AboyansV , RiccoJB , BartelinkME , BjörckM , BrodmannM , CohnertT , et al, ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal2018;39(9):763-816.">Aboyans 2018</a>; <a href="./references#CD003748-bbs2-0058" title="Gerhard-HermanMD , GornikHL , BarrettC , BarshesNR , CorriereMA , DrachmanDE , et al. 2016 AHA/ACC Guidelines on the Management of Patients with Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology2017;69:e71-e126.">Gerhard‐Herman 2017</a>; <a href="./references#CD003748-bbs2-0049" title="AboyansV , RiccoJB , BartelinkME , BjörckM , BrodmannM , CohnertT , et al, ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal2018;39(9):763-816.">Aboyans 2018</a>), are suggested by some national guidelines. A review of clinical guidelines published in 2016 showed that cilostazol was the most recommended drug (in five guidelines) as first option for pharmacological treatment (<a href="./references#CD003748-bbs2-0051" title="BarriocanalAM , LopezAM , FarreM , MontaneE . Recommendations of intermittent claudication symptomatic treatment in peripheral arterial disease clinical practice guidelines. Basic and Clinical Pharmacology and Toxicology2016;119(Suppl 1):53.">Barriocanal 2016</a>). </p> <p>Although the data supports the use of cilostazol for the treatment of intermittent claudication in people with PAD, as well as pentoxifylline and inositol nicotinate, current NICE guidelines (last updated December 2020) only recommend naftidrofuryl as treatment in this population (<a href="./references#CD003748-bbs2-0071" title="National Institute for Health and Care Excellence (NICE). Peripheral arterial disease: diagnosis and management (last updated December 2020). nice.org.uk/Guidance/CG147 (accessed 12 March 2021).">NICE 2012</a>). Our review, alongside other reviews mentioned here, demonstrates that there remains a degree of uncertainty as to which, if any, of these medications provides most clinical benefit. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003748-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003748-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003748-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003748-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 1: Initial claudication distance (ICD)" data-id="CD003748-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 1: Initial claudication distance (ICD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 2: Absolute claudication distance (ACD)" data-id="CD003748-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 2: Absolute claudication distance (ACD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 3: Arterial revascularisation" data-id="CD003748-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 3: Arterial revascularisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 4: Amputation" data-id="CD003748-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 4: Amputation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 5: Adverse event related to study medication ‐ headache" data-id="CD003748-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 5: Adverse event related to study medication ‐ headache </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 6: Adverse event related to study medication ‐ diarrhoea" data-id="CD003748-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 6: Adverse event related to study medication ‐ diarrhoea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 7: Adverse event related to study medication ‐ abnormal stools" data-id="CD003748-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 7: Adverse event related to study medication ‐ abnormal stools </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 8: Adverse event related to study medication ‐ dizziness" data-id="CD003748-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 8: Adverse event related to study medication ‐ dizziness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 9: Adverse event related to study medication ‐ pain" data-id="CD003748-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 9: Adverse event related to study medication ‐ pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 10: Adverse event related to study medication ‐ palpitations" data-id="CD003748-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 10: Adverse event related to study medication ‐ palpitations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 11: Cardiovascular event" data-id="CD003748-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 11: Cardiovascular event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 12: All‐cause mortality" data-id="CD003748-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 12: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 13: Ankle brachial index (ABI)" data-id="CD003748-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 13: Ankle brachial index (ABI)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 14: Initial claudication distance (ICD) sensitivity analysis" data-id="CD003748-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 14: Initial claudication distance (ICD) sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 15: Absolute claudication distance (ACD) sensitivity analysis" data-id="CD003748-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 15: Absolute claudication distance (ACD) sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 16: Adverse event related to study medication ‐ headache, sensitivity analysis" data-id="CD003748-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 16: Adverse event related to study medication ‐ headache, sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 17: Adverse event related to study medication ‐ diarrhoea, sensitivity analysis" data-id="CD003748-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 17: Adverse event related to study medication ‐ diarrhoea, sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 18: Adverse event related to study medication ‐ pain, sensitivity analysis" data-id="CD003748-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 18: Adverse event related to study medication ‐ pain, sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 19: Adverse event related to study medication ‐ palpitations, sensitivity analysis" data-id="CD003748-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 19: Adverse event related to study medication ‐ palpitations, sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cilostazol versus placebo, Outcome 20: All‐cause mortality sensitivity analysis" data-id="CD003748-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Cilostazol versus placebo, Outcome 20: All‐cause mortality sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 1: Initial claudication distance (ICD)" data-id="CD003748-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 1: Initial claudication distance (ICD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 2: Absolute claudication distance (ACD)" data-id="CD003748-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 2: Absolute claudication distance (ACD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 3: Adverse event related to study medication ‐ headache" data-id="CD003748-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 3: Adverse event related to study medication ‐ headache </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 4: Adverse event related to study medication ‐ diarrhoea" data-id="CD003748-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 4: Adverse event related to study medication ‐ diarrhoea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 5: Adverse event related to study medication ‐ abnormal stools" data-id="CD003748-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 5: Adverse event related to study medication ‐ abnormal stools </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 6: Adverse event related to study medication ‐ pain" data-id="CD003748-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 6: Adverse event related to study medication ‐ pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 7: Adverse event related to study medication ‐ palpitations" data-id="CD003748-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 7: Adverse event related to study medication ‐ palpitations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 8: All‐cause mortality" data-id="CD003748-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 8: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003748-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/urn:x-wiley:14651858:media:CD003748:CD003748-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 9: Ankle brachial index (ABI)" data-id="CD003748-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_t/tCD003748-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily, Outcome 9: Ankle brachial index (ABI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/media/CDSR/CD003748/image_n/nCD003748-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003748-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cilostazol compared with placebo for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cilostazol compared with placebo for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> intermittent claudication<br/><b>Setting:</b> all outpatient settings<br/><b>Intervention:</b> cilostazol<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cilostazol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial claudication distance</b> </p> <p>(change in metres)</p> <p>12 to 24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in initial claudication distance was 32.28</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 26.49 higher<br/>(18.93 higher to 34.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1722<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p>(change in points/ percentage; COM, SF‐36, VascuQol, WIQ)</p> <p>16 to 24 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There appeared to be a general improvement of cilostazol over placebo across four studies that used the SF‐36 (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>). </p> <p>There were inconsistent results for walking impairment according to the WIQ (4 studies), three studies showed no difference between groups for walking impairment (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>; <a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>) and one study reported a 20% increase in walking speed for the cilostazol group (<a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Money 1998</a>). </p> <p>There were modest improvements across the domains of the COM in one study (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>). </p> <p>There was no difference between groups in one study using the VascuQol questionnaire (<a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1163</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOW <sup>2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meta‐analysis was not undertaken because of differences in measures used and how they were reported. See <a href="./full#CD003748-tbl-0002">Table 1</a> for further details. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Absolute claudication distance</b> </p> <p>(change in metres)</p> <p>12 to 24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in absolute claudication distance was 37.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 39.57 higher<br/>(21.8 higher to 57.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2360<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 4, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Arterial revascularisation</b> </p> <p>(number of cases)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.16<br/>(0.01 to 4.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>516<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Amputation</b> </p> <p>(number of cases)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.16<br/>(0.01 to 4.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>516<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event related to study medication ‐</b> </p> <p><b>headache</b> </p> <p>(number of cases)</p> <p>12 to 26 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.83<br/>(2.26 to 3.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2584<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2, 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000<br/>(210 to 295) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cardiovascular event</b> </p> <p>(number of cases)</p> <p>24 to 26 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 1.50<br/>(0.51 to 4.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>692<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000<br/>(8 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>COM:</b> Claudication Outcome Measure; <b>OR</b> : odds ratio; <b>SF‐36:</b> self‐administered Short‐form 36; <b>VascuQol:</b> Vascular Quality of Life; <b>WIQ:</b> Walking Impairment Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded by one level for risk of bias because 3 studies (<a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) rated at high risk for selective reporting </p> <p><sup>2</sup> downgraded by one level for publication bias because pharmaceutical sponsors involvement in most of these studies raises questions of whether unpublished studies that suggest no benefit exist </p> <p><sup>3</sup> downgraded by one level for imprecision because a range of quality of life measurement tools were used and results were reported in different ways (meta‐analysis was not undertaken for these reasons) </p> <p><sup>4</sup> downgraded by one level for risk of bias because 4 studies (<a href="./references#CD003748-bbs2-0003" title="DawsonDL , CutlerBS , MeissnerMH , Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation1998;98(7):678-86. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 1998</a>; <a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) rated at high risk for selective reporting </p> <p><sup>5</sup> downgraded by one level for inconsistency because of heterogeneity: I<sup>2</sup> = 72% cilostazol 100 mg twice daily versus placebo subgroup ‐ heterogeneity reduced to 0% when 2 studies removed (<a href="./references#CD003748-bbs2-0014" title="Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐95‐201</a>; <a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a>) </p> <p><sup>6</sup> downgraded by two levels for imprecision due to low number of participants and events from 1 RCT (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>) </p> <p><sup>7</sup> see <a href="./full#CD003748-tbl-0003">Table 2</a> for other adverse events related to study medication </p> <p><sup>8</sup> downgraded by one level for imprecision due to low number of participants and events from 2 RCTs (<a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Beebe 1999</a>; <a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cilostazol compared with placebo for intermittent claudication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003748-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Change in quality of life status (change in points or percentage from baseline)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0001" title="BeebeHG , DawsonDL , CutlerBS , HerdJA , Strandness DE Jr, BorteyEB , et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine1999;159(17):2041-50. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). "><b>Beebe 1999</b> </a> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). "><b>Dawson 2000</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0008" title="MoneySR , HerdJA , IsaacsohnJL , DavidsonM , CutlerB , HeckmanJ , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery1998;27(2):267-74. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). "><b>Money 1998</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. "><b>O'Donnell 2009</b> </a> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg (n = 137)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 50 mg (n = 135)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n = 141)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg (n = 205)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pentox 400 mg (n = 212)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n = 226</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg (n = 119)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n =  120)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cilostazol 100 mg ( n = 39)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (n = 41)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Short‐form 36</b> (SF‐36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physical function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Role‐physical</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no improv</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no improv</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bodily pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Social function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Role‐emotional</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mental health</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General health</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Walking Impairment Questionnaire</b> (WIQ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walking speed</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walking distance</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no diff</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>Claudication Outcome Measure</b> (COM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in pain/discomfort</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain/discomfort: daily activities</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain/discomfort: physical activities</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain/discomfort: social activities</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walking pain/discomfort</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worry/concern due to pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Vascular Quality of Life</b> (VascuQol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activity</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptom</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotion</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Social</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>diff: difference<br/>improv: improvement<br/>Pentox: pentoxifylline </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Change in quality of life status (change in points or percentage from baseline)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003748-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events related to study medication</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or pentoxifylline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cilostazol</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cilostazol compared to placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Diarrhoea</b> </p> <p>12 to 26 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.73<br/>(2.02 to 3.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2503<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000<br/>(108 to 181) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Abnormal stools</b> </p> <p>12 to 24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.63<br/>(2.45 to 5.38) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1804<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/>(101 to 198) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>12 to 26 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.42<br/>(1.43 to 4.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1120<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/>(60 to 153) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>12 to 24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.96<br/>(0.71 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1572<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/>(94 to 159) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Palpitations</b> </p> <p>24 to 26 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 7.16<br/>(3.95 to 12.98) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1681<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1, 3</sup> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 per 1000<br/>(60 to 173) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cilostazol compared to pentoxifylline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Diarrhoea</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 1.80<br/>(0.79 to 4.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>982<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1, 3, 4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162 per 1000<br/>(78 to 307) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Abnormal stools</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 3.12<br/>(1.57 to 6.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>459<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145 per 1000<br/>(79 to 253) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Pain</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 0.85<br/>(0.57 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>982<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 per 1000<br/>(74 to 151) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Palpitations</b> </p> <p>24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 8.35<br/>(4.11 to 16.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>982<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134 per 1000<br/>(71 to 240) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> downgraded one level for publication bias because pharmaceutical sponsors involvement raises questions of whether unpublished studies that suggest no benefit exist </p> <p><sup>2</sup> downgraded one level for risk of bias because 2 studies (<a href="./references#CD003748-bbs2-0006" title="ElamMB , HeckmanJ , CrouseJR , HunninghakeDB , HerdJA , DavidsonM , et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology1998;18(12):1942-7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Elam 1998</a>; <a href="./references#CD003748-bbs2-0016" title="Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). Strandness DE Jr, DalmanRL , PanianS , RendellMS , CompPC , ZhangP , et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery2002;36(2):83-91. ">Strandness 2002</a>) rated at high risk for selective reporting </p> <p>3 downgraded one level for imprecision due to wide CIs</p> <p>4 downgraded one level for inconsistency because of heterogeneity: I² = 77%</p> <p><sup>5</sup> downgraded one level for imprecision due to data from 1 RCT with wide CIs (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events related to study medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003748-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cilostazol compared with pentoxifylline for intermittent claudication</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cilostazol 100 mg twice daily compared with pentoxifylline 400 mg twice daily for intermittent claudication</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> intermittent claudication<br/><b>Setting:</b> all outpatient settings<br/><b>Intervention:</b> cilostazol 100 mg twice daily<br/><b>Comparison:</b> pentoxifylline 400 mg three times daily </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pentoxifylline 400 mg twice daily</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cilostazol 100 mg twice daily</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Initial claudication distance</b> </p> <p>(change in meters)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in initial claudication distance was 73.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20.00 higher<br/>(2.57 lower to 42.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p>(change in points, SF‐36, WIQ)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Quote "None of the treatments significantly affected the Medical Outcomes Scale Short Form‐36 scores on Mental Health Concepts, General Health Perception, Physical Health Concepts, or Vitality Scores. There were also no<br/>significant differences in patient‐reported walking distance or speed as determined by the Walking Impairment Questionnaire." (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>317</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Absolute claudication distance</b> </p> <p>(change in metres)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in absolute claudication distance was 70.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 13.43 higher<br/>(43.50 lower to 70.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>866<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2, 4, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arterial revascularisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amputation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event related to study medication ‐ headache</b> </p> <p>(number of cases)</p> <p>24 weeks follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.20<br/>(1.16 to 4.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>982<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/>(127 to 343) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>SF‐36:</b> self‐administered Short‐form 36; <b>WIQ:</b> Walking Impairment Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one level for imprecision because 1 RCT had a low number of participants (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>) </p> <p><sup>2</sup> downgraded one level because publication bias strongly suspected </p> <p><sup>3</sup> downgraded by two levels for imprecision because 1 RCT had a low number of participants (<a href="./references#CD003748-bbs2-0004" title="DawsonDL , CutlerBS , HiattWR , Hobson RW 2nd, MartinJD , BorteyEB , et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine2000;109(7):523-30. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Dawson 2000</a>) and imprecision could not be evaluated </p> <p><sup>4</sup> downgraded one level for inconsistency because of heterogeneity: I<sup>2 </sup>≥ 50% </p> <p><sup>5</sup> downgraded one level for imprecision due to very wide CIs </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cilostazol compared with pentoxifylline for intermittent claudication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003748-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reasons for study not being included in meta‐analyses of initial claudication distance (ICD), absolute claudication distance (ACD) and ankle brachial index (ABI)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reason for data not included in ICD, ACD or ABI outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0002" title="BrassEP , CooperLT , MorganRE , HiattWR . A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery2012;55(2):381-9. HiattWR , CooperLT , MorganRE , BrassEP . Clinical effects of the phosphodiesterase inhibitor K-134 in peripheral artery disease and claudication. Circulation2011;124(Suppl 21):A9800. LewisRJC . Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials2011;12:134. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (first posted 31 October 2008). ">Brass 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported in peak walking time and initial claudication time with SDs, but the treadmill method was not clear, so we could not reliably convert from time to distance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0005" title="De AlbuquerqueRM , Virgini-MagalhãesCE , LencastreSF , BottinoDA , BouskelaE . Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology2008;59(5):549-58. ">De Albuquerque 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes of interest were only broken down between non‐smokers and smokers, but not between treatment groups. Figures 2 and 3 do offer graphical information on the mean change in maximal walking distances, 'expressed as percent of control'. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0007" title="LeeTM , SuSF , HwangJJ , TsengCD , ChenMF , LeeYT , et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis2001;158(2):471-6. LeeTM , SuSF , TsaiCH , LeeYT , WangSS . Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science2001;101(3):305-11. ">Lee 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For ACD and ABI, mean baseline and follow‐up values with SD were given; we can calculate mean change but for the imputation of SD we need the SDs associated with the change and the baseline and the post‐intervention mean, for at least one similar length study, which we do not have. Mean changes in ACD without SD or other variance were also reported in the text. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0009" title="O'DonnellM , BadgerSA , SharifMA , YoungIS , LauLL , LeeB , et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. In: European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43. O'DonnellME , BadgerSA , MakarRR , McEnenyJ , YoungIS , LauLL , et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain and Ireland Yearbook2007:49. O'DonnellME , BadgerSA , MakarRR , YoungIS , LauLL , LeeB , et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain and Ireland Yearbook2007:82. O'DonnellME , BadgerSA , SharifMA , MakarRR , McEnenyJ , YoungIS , et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2009;37(3):326-35. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology2008;59(6):695-704. O'DonnellME , BadgerSA , SharifMA , MakarRR , YoungIS , LeeB , et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery2009;43(2):132-43. O'DonnellME , BadgerSA , SharifMA , YoungIS , LeeB , SoongCV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery2009;49(5):1226-34. ">O'Donnell 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For ICD and ACD, mean baseline and follow‐up values were given, but no SDs were given. A P value was given for the overall treatment effect but that was for the comparison between cilostazol and placebo, not between baseline and follow‐up. For ABI only, interquartile ranges were given, which could not be adequately converted to SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0010" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo‐corrected mean change from baseline was provided for the treatment group, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and placebo, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0011" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐86‐103</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raw mean change from baseline was provided for the cilostazol and placebo groups, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and placebo, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0012" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐87‐101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo‐corrected mean change from baseline was provided for the treatment group, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and placebo, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0013" title="Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014). ">Otsuka Study 21‐94‐301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the ICD outcome, only a ratio of the geometric means of change was calculated between cilostazol and the comparison, but these data could not be recalculated to mean change and SD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003748-bbs2-0015" title="Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease (accessed prior to 16 June 2021). European Medicines Agency. Assessment report for Cilostazol containing medicinal products. ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cilostazol_31/WC500148976.pdf (accessed prior to 22 June 2021). ">Otsuka Study 21‐98‐213</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For ICD, raw mean change from baseline was provided for the cilostazol and comparison groups, with no SDs. Also, a ratio of the geometric means of change was calculated between cilostazol and comparisons, but these data could not be recalculated to mean change and SD. Mean change data with SDs were available for the ACD outcome. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>ACD: absolute claudication distance<br/>ABI: ankle brachial index<br/>ICD: initial claudication distance<br/>SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reasons for study not being included in meta‐analyses of initial claudication distance (ICD), absolute claudication distance (ACD) and ankle brachial index (ABI)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/full#CD003748-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003748-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cilostazol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Initial claudication distance (ICD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.49 [18.93, 34.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.50 [6.80, 32.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>32.19 [22.20, 42.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Cilostazol 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.70 [‐12.20, 43.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Absolute claudication distance (ACD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.57 [21.80, 57.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.84 [8.81, 52.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>42.32 [18.12, 66.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Cilostazol 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>51.80 [‐10.59, 114.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Arterial revascularisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 4.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Amputation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 4.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse event related to study medication ‐ headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [2.26, 3.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.19, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [2.38, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse event related to study medication ‐ diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [2.02, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.91, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [2.07, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse event related to study medication ‐ abnormal stools <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [2.45, 5.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [1.08, 5.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.04 [2.59, 6.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse event related to study medication ‐ dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.43, 4.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.63, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.42, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse event related to study medication ‐ pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.71, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.67, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Adverse event related to study medication ‐ palpitations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.16 [3.95, 12.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.89 [0.51, 155.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.06 [3.85, 12.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Cardiovascular event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.51, 4.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.30, 7.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.35, 6.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.41, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.03, 8.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.42, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Ankle brachial index (ABI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Initial claudication distance (ICD) sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.52 [21.26, 37.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.50 [6.80, 32.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>36.86 [25.98, 47.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Absolute claudication distance (ACD) sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>48.44 [34.49, 62.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.84 [8.81, 52.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>56.30 [40.37, 72.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Adverse event related to study medication ‐ headache, sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [2.21, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.19, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [2.35, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Adverse event related to study medication ‐ diarrhoea, sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [2.05, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.91, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [2.15, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Adverse event related to study medication ‐ pain, sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.75, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.67, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.66, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Adverse event related to study medication ‐ palpitations, sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.80 [5.06, 32.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.89 [0.51, 155.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.42 [5.05, 35.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 All‐cause mortality sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.47, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Cilostazol 50 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.03, 8.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Cilostazol 100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.49, 3.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cilostazol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003748-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Initial claudication distance (ICD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.00 [‐2.57, 42.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Absolute claudication distance (ACD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.43 [‐43.50, 70.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Adverse event related to study medication ‐ headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.16, 4.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse event related to study medication ‐ diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.79, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Adverse event related to study medication ‐ abnormal stools <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [1.57, 6.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Adverse event related to study medication ‐ pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse event related to study medication ‐ palpitations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.35 [4.11, 16.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.17, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Ankle brachial index (ABI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.12, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cilostazol 100 mg twice daily versus pentoxifylline 400 mg three times daily</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003748.pub5/references#CD003748-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003748.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003748-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003748-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003748-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD003748-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003748-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003748-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD003748-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003748-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003748\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003748\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003748\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003748\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003748\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003748.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003748.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003748.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003748.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003748.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714256267"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003748.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714256271"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003748.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6a3dcfeef3cd',t:'MTc0MDcxNDI1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 